,0,1
0,managerial assistance&quot,9.67129119075484
1,financial statements&quot,9.016857397481452
2,executive officer,9.0
3,thermal solutions,9.0
4,fide executive,9.0
5,undue reliance,9.0
6,tremendous attention,9.0
7,continuous progression,9.0
8,lending standards,8.8
9,managerial assistance,8.728886422493526
10,financial officer,8.676646706586826
11,financial solutions,8.676646706586826
12,biomedical holdings,8.619138053001034
13,currency translation,8.508647798742139
14,insider trading policies,8.497474747474747
15,lenders party thereto,8.477272727272727
16,statutory obligation,8.4
17,actuarial gains,8.333333333333334
18,scenarios,8.325
19,unconditional firm,8.321428571428571
20,water absorbents,8.294117647058822
21,currency rates,8.276089659207255
22,fleet health alliance,8.275862068965518
23,pharma corporation,8.271144278606965
24,promissory notes,8.2375
25,enumeral biomedical,8.223950887225634
26,operating officer,8.223880597014926
27,office space,8.215277777777779
28,managerial assistance,8.196253369272238
29,market makers,8.186186186186186
30,secured debt,8.18576753642833
31,cambrios technologies corporation,8.18512277323062
32,breakpoints,8.105072463768115
33,laser light engines,8.09090909090909
34,holding periods,8.042553191489361
35,general partner,8.032581453634085
36,recurring accruals,8.0
37,microeconomic events,7.978846153846154
38,therapeutics corporation,7.898595258999122
39,affiliated companies,7.894108527131783
40,disruptive technologies,7.893145161290322
41,option premiums,7.880298507462687
42,option theory,7.875081116158339
43,owned subsidiaries,7.85704918032787
44,partner companies,7.7912513842746405
45,local taxes,7.781818181818181
46,offering scenarios,7.731678486997636
47,liquidity requirements,7.726412745830221
48,adesto technologies corporation,7.717590305698153
49,silicon holdings,7.712951969778737
50,average rate,7.710352469846141
51,interest rates,7.698098794771685
52,interest rates,7.698098794771685
53,holding periods,7.675464583894424
54,rise,7.655172413793103
55,corporate capital,7.640457932822119
56,option exercise patterns,7.63384689455946
57,commitment fee,7.630102040816327
58,bridge notes,7.594642857142857
59,contributing factor,7.59356585443542
60,fee income,7.574481865284974
61,managerial assistance,7.566503022531599
62,mailing date,7.562091503267974
63,financial statements,7.556588641519795
64,weighted average based,7.556165674354997
65,financial information,7.545805585091499
66,owned subsidiary,7.543715846994536
67,financial statements,7.54181957599885
68,macroeconomic events,7.529284750337382
69,limited partner,7.513392857142858
70,reporting purposes,7.50998003992016
71,credit agency,7.5
72,secured debt,7.492219149331555
73,affiliated company,7.479913106444606
74,adesto technologies,7.476749057394219
75,public market,7.473420228739378
76,bid quotations,7.472222222222223
77,employee bonus expense,7.469764224361561
78,option pricing models,7.456929536210607
79,financial statements,7.440942383016394
80,debt issuance costs,7.439185086620073
81,technologies,7.43778801843318
82,lattice model,7.435897435897436
83,consolidated statements,7.432588599749102
84,regulatory approvals,7.4302059496567505
85,significant subsidiaries,7.4228571428571435
86,converged standard,7.4
87,investment advisers,7.397887323943662
88,notes thereto,7.3875
89,financial instruments,7.376646706586826
90,exemptive order,7.371428571428572
91,traded stock,7.366512771790228
92,exercise behavior,7.359377532825418
93,lower costs,7.346774193548387
94,potential contribution,7.325
95,accounting pronouncements,7.31031746031746
96,year nqsos,7.297235023041475
97,insurance premiums,7.287368421052632
98,pricing services,7.2787439613526566
99,unaffiliated companies,7.256689172293074
100,capital market,7.252176033901922
101,accounting policies,7.250649350649351
102,compensation cost,7.247477022887007
103,tax savings,7.245990796262725
104,traded companies,7.228399076699788
105,stock exchanges,7.218055555555556
106,preferred stock,7.216666666666667
107,forfeiture rate,7.207919973544973
108,debt expense,7.2068447048739195
109,existing privately held,7.2058725917039315
110,months,7.204751548292219
111,actual awards,7.202671312427411
112,net asset,7.200914118912275
113,public listing,7.194760924273621
114,september30,7.1903173145597385
115,option pricing model,7.166051015823891
116,insurance expense,7.162847900801941
117,operating companies,7.157989124146709
118,borrowing capacity,7.148148148148149
119,sublease income,7.142339008142117
120,liquidity scenarios,7.1385922330097085
121,common stock,7.131481481481481
122,valuation firm,7.128618113912232
123,venture debt deal,7.126638713444084
124,discount rate,7.122004357298475
125,unrealized gains,7.118567526251159
126,china electronics corporation,7.117298124760811
127,trading market,7.1097972972972965
128,significant subsidiary,7.109523809523809
129,loan facility,7.0999355847126004
130,additional capital,7.094158861800243
131,venture environments,7.080670508119434
132,principal,7.075818036711892
133,program purchases,7.068084784826388
134,accounting policies,7.0577922077922075
135,cash flow,7.056527303754266
136,market data,7.050702315218444
137,secondary liquidity,7.042860525692635
138,financial liabilities,7.030094982448896
139,intercompany accounts,7.026190476190476
140,stock option awards,7.024715851636127
141,hierarchical levels,7.018181818181818
142,goal,7.015873015873016
143,additional repayments,7.0068924183398265
144,valuation committee book,7.001633986928105
145,valuation committee,7.001633986928105
146,products,7.0
147,portfolio companies,6.99625541978715
148,portfolio companies,6.99625541978715
149,financial information,6.994785176928234
150,income tax,6.991771732569575
151,income taxes,6.981300047103155
152,unaudited notes,6.980163255089554
153,method,6.979613241560144
154,unrealized depreciation,6.976538540743912
155,debt investment,6.9721163988335295
156,stock price,6.970452310717798
157,public information,6.956392921057864
158,revenue standards,6.952204836415363
159,office space,6.949971655328798
160,interest rates,6.948098794771685
161,unrealized appreciation,6.944325102008735
162,liquidity events,6.942438386855862
163,cash reserves,6.935909222573454
164,growth potential,6.925
165,champions oncology,6.921293199554069
166,capital loss carryforwards,6.919648384301102
167,capital loss carryforward,6.919648384301102
168,amp,6.9186507936507935
169,retrospective approach,6.910818713450292
170,invested capital,6.9089650543273065
171,corporate headquarters,6.907801418439716
172,rent expense,6.9059556702255005
173,tradable shares,6.902681992337165
174,ten equity,6.901029932410685
175,held portfolio,6.8995984317277195
176,traded securities,6.89951930773794
177,business environment,6.8975044199646405
178,precision medicine market,6.89681237214444
179,market interest rates,6.884284980957872
180,rent expense,6.8730918204602425
181,large rounds,6.86525974025974
182,offering price,6.864413663374803
183,interest rates,6.863927940500329
184,performance target,6.855392156862745
185,market quotations,6.852852852852854
186,debt investments,6.847593560871176
187,restricted securities,6.839603758169934
188,public offering,6.839205368718066
189,future amounts,6.824559304458802
190,loss relate,6.821049840933192
191,average ownership,6.820323979817651
192,additional meetings,6.820050932903696
193,valuation committee meeting,6.819815805109923
194,stock awards,6.818792344173442
195,traded investments,6.817655035549314
196,qualifying assets,6.814486139283299
197,traded company,6.8142036560126105
198,investment capabilities,6.813716469672306
199,contour energy systems,6.808333333333334
200,market quotations,6.806753562072711
201,ascertainable market,6.801570801570801
202,net gains,6.801391876878718
203,gains,6.801391876878718
204,operating commitment,6.7989826378312515
205,dividend rate,6.796983044425501
206,bridge notes,6.794642857142858
207,retirement benefit obligation,6.793939393939395
208,medical benefit,6.793939393939394
209,ten investments,6.792595255212078
210,stock price,6.788634128899616
211,operating income,6.787320059473044
212,biotechnology companies,6.7802623732856295
213,gains,6.777859811620466
214,proceeds,6.77637859246471
215,preferred equity,6.776243607624361
216,merton pricing model,6.773371555980251
217,held companies,6.7715600662041355
218,compensation expense,6.768870889451091
219,income tax expense,6.76658594411391
220,service period,6.766381766381767
221,accounting policy,6.766256157635468
222,debt obligations,6.750973260936379
223,investment advisory services,6.747887323943662
224,transformative companies,6.746608527131783
225,operating company,6.743793703459531
226,medical technologies,6.741514726507713
227,preferred stock,6.732456140350878
228,option price models,6.731971218909081
229,debt securities,6.731867471614018
230,venture capital portfolio,6.73054637892532
231,additional repayments,6.728169014084507
232,debt,6.7251147431668405
233,shareholder communications,6.723529411764705
234,additional capital,6.719158861800243
235,financial assets,6.699466179203459
236,unfunded commitments,6.6903703703703705
237,conversion ratio,6.688282647584973
238,basic approaches,6.6875
239,stock prices,6.6839243498817975
240,compensation expense,6.681980243864794
241,professional fees,6.677142456730433
242,custody fees,6.677142456730433
243,based inventions,6.676501035196687
244,option contracts,6.6750811161583385
245,enable preparation,6.666666666666666
246,regulatory approvals,6.666580910728068
247,precision health,6.662958843159066
248,health care costs,6.6583505482281895
249,plan amendments,6.65625
250,venture debt investments,6.6500031994253925
251,secondary liquidity,6.647932989460751
252,precision medicine companies,6.644734713090037
253,custody fees,6.644278606965175
254,professional fees,6.644278606965175
255,traded shares,6.641416986349615
256,future events,6.630786410685909
257,cost basis,6.629974850362377
258,financing charges,6.629124767225326
259,venture capital industry,6.6273035958589945
260,remaining principal outstanding,6.62026455026455
261,market expectations,6.6129303722326975
262,significant estimates,6.60952380952381
263,put options,6.606060606060607
264,stock price,6.603363703122861
265,benefits,6.6
266,financial statements,6.59541392773184
267,investment group,6.592004971002485
268,portfolio investments,6.585511378636675
269,distribution requirement,6.583333333333334
270,accrued interest,6.566371220020855
271,fees,6.563326226012793
272,equity method investees,6.552153145480801
273,cash premiums,6.5479849009274105
274,harris partners,6.5436507936507935
275,event,6.541779497098647
276,gain,6.529702379161822
277,stock award,6.523988526570049
278,realized gain,6.506170313903572
279,precision medicine markets,6.500749642748378
280,milestone payments,6.500372588311151
281,operating expenses,6.498703292050386
282,liquidity events,6.492438386855863
283,capital gain,6.491591280505319
284,remaining funds,6.491473755553882
285,net assets,6.482930915943625
286,life sciences portfolio,6.482450497968459
287,funding environments,6.478260869565217
288,milestone payments,6.474218742157305
289,debt investments,6.469815783093398
290,business plan,6.4575657894736835
291,interest,6.450570040751174
292,capitalization companies,6.445080313965638
293,held securities,6.442680297242287
294,operating loss,6.441496730773435
295,stock plan,6.436805555555557
296,environmental impact,6.436582109479306
297,substantial risks,6.428571428571429
298,security,6.419994685797794
299,subsequently declared worthless,6.41764705882353
300,potential sales,6.401923076923077
301,meaningful growth,6.4
302,service period,6.39929315878683
303,operating losses,6.397362003711879
304,distributable income,6.395400232631912
305,demand notes,6.394907407407407
306,cobalt technologies,6.381613423797047
307,life sciences industry,6.379207714902134
308,precision health,6.373018014756699
309,month period,6.368444055944057
310,investment diversification requirements,6.367604388488313
311,business strategy,6.364171086631307
312,compensation expenses,6.361077954502501
313,investments,6.360816025053661
314,held company,6.357364645516958
315,investor,6.354969574036511
316,warrant coverage,6.34909377462569
317,debt,6.348549193023188
318,venture capital firms,6.33506615293662
319,low yields,6.333333333333333
320,portfolio company,6.332059999099972
321,portfolio companies,6.329588753120484
322,retirement benefit cost,6.326900287794143
323,net realizations,6.3248271623905366
324,financing requirements,6.321107759107815
325,milestone payments,6.3200478878859485
326,primary liquidity,6.31959009987714
327,party transactions,6.315347018572824
328,interest rate volatility,6.3149161935658285
329,liquidity,6.313592233009708
330,relevant information,6.312016021361816
331,settlement procedures,6.308855556356818
332,diversification tests,6.302134646962234
333,management depth,6.2983268983268985
334,realized loss,6.298185014872499
335,agency securities,6.2971106769891225
336,services company,6.296559813031431
337,debt funds,6.294143492269723
338,common stock,6.28888888888889
339,cash rent expense,6.283785790881175
340,periodic post,6.282086252143905
341,net losses,6.277582353069193
342,focused portfolio,6.275767941909338
343,exemptive order&quot,6.275037821482602
344,insurance,6.271688539185951
345,taxes,6.268939393939394
346,sec certifications,6.264437689969605
347,payment awards,6.260678438432514
348,investment management,6.260499936556275
349,enhancing fees,6.256335344553827
350,quoted prices,6.254559270516717
351,sufficient capital,6.251704133430022
352,producing investment,6.247369189228635
353,amounts,6.247296050203027
354,income approach,6.229978668039524
355,stock options,6.22962962962963
356,stock options,6.229629629629629
357,portfolio companies,6.222999605833661
358,interest income recognition,6.221047890500635
359,future payments,6.214300761449167
360,similar businesses,6.213131313131313
361,market transactions,6.210624113849921
362,securities exchange act,6.207080610021786
363,portfolio companies,6.206781735576624
364,interim periods,6.20159195492373
365,net asset,6.200914118912275
366,stock basis,6.195584045584045
367,employee stock options,6.192704149933066
368,venture capital investments,6.191763972251262
369,operating expenses,6.190622483969578
370,investment,6.18976924276285
371,portfolio securities,6.189114781260084
372,venture capital company,6.188312592714558
373,portfolio companies,6.188137338606339
374,closed trading,6.183333333333334
375,investment income,6.180702522561969
376,quoted prices,6.179792915376531
377,asset base,6.17747376311844
378,eleven months,6.171212121212121
379,investment company,6.167800430388267
380,investment company,6.167800430388267
381,input assumptions,6.156462585034014
382,debt liability,6.154351191579149
383,investment pace,6.152409287767951
384,based compensation,6.146861320073101
385,volatility assumptions,6.146308523409364
386,tax treatment,6.143747708104144
387,valuation,6.1395650214108635
388,average shares,6.13744523659408
389,rounding adjustments,6.131239935587762
390,stock price appreciation,6.129543219808706
391,board members,6.128747795414462
392,market sales,6.117654717654718
393,enhanced disclosures,6.115708274894811
394,multiple exits,6.109151451422744
395,realized returns,6.10410094637224
396,capital,6.1019475104676575
397,fair valuations,6.0973382317263365
398,funds,6.096707400413695
399,historical data,6.09505800095344
400,additional capital,6.094158861800243
401,realized returns,6.092412634683928
402,future growth,6.090829145728644
403,option holders,6.089366830444053
404,deal team,6.088888888888889
405,unrealized depreciation,6.0789674981926165
406,exit environments,6.078260869565217
407,life science,6.076668373442567
408,financing,6.0765666276904415
409,portfolio day,6.074541631987376
410,life science companies,6.067919757717207
411,quarter,6.055503006061219
412,lower valuations,6.051865460712266
413,net asset,6.050914118912276
414,series seed financing,6.050621365864782
415,unrealized change,6.043854882572998
416,significant estimate,6.041694352159468
417,discount rate assumptions,6.04037170423725
418,cash flows,6.038888707547425
419,december31,6.034858921341906
420,prices,6.031399097356545
421,stock option increases,6.030593018841535
422,tax benefits,6.028536067892503
423,similar securities,6.027450980392157
424,round led&quot,6.021191667636448
425,portfolio companies,6.017994550221933
426,preferred equity,6.0147051460859
427,accelerator corporation,6.011319717203456
428,indemnity claims,6.009411764705883
429,interest entity,6.007187546551467
430,income taxes&quot,6.001792414040303
431,market approach,6.001508515678556
432,stock options,5.997455867082035
433,portfolio companies,5.99625541978715
434,day operating expenses,5.985882779229874
435,deferred rent&quot,5.985514011958792
436,term income,5.97567234147545
437,operations,5.973852685490936
438,financial assets,5.972308818797368
439,net proceeds,5.9705879781726505
440,gross proceeds,5.959158196732474
441,closing conditions,5.952386036084125
442,york corporation,5.947267210049045
443,portfolio companies,5.943623840839782
444,operations,5.940988835725678
445,expected volatility,5.938000348068222
446,interest rate analysis,5.929046628348437
447,low valuations,5.920344682639764
448,payment accounting,5.9199118879098656
449,investment company,5.917800430388267
450,total investments,5.9148141943324255
451,market price,5.9079456864464674
452,tax,5.905917020273456
453,illiquid securities,5.905228758169935
454,life,5.895341426795695
455,based compensation&quot,5.894626414282976
456,business plan,5.893929425837321
457,comprehensive income&quot,5.891910991115402
458,preferred stock&quot,5.891704488149269
459,total investments,5.8819503445671675
460,prior period,5.877353640511536
461,investment income,5.872621714481161
462,securities laws,5.864488017429194
463,enumeral biomedical,5.8603145235892695
464,term assumptions,5.854641856742697
465,net cash,5.8487256416681515
466,retirement benefit plans,5.8484848484848495
467,management,5.823560543186711
468,income,5.819394971729579
469,expenses&quot,5.816527183184729
470,outstanding classes,5.804935318093213
471,stock price,5.793981722482504
472,interest rates,5.790691387364278
473,retirement plan,5.778637669801464
474,total amounts,5.776575276575277
475,net asset,5.772342690340846
476,private company,5.768924964152116
477,loan facility,5.761625800655016
478,investment opportunities,5.758998435054773
479,benefits,5.756043956043956
480,trading range,5.74537037037037
481,additional payments,5.739747425921536
482,ric income,5.7391644049675135
483,bridge,5.732044198895028
484,exit environment,5.722705314009662
485,intellectual property,5.715617715617716
486,call options,5.711378353376503
487,withholding tax,5.71119048244347
488,current period,5.710718545020871
489,operating results,5.710022242743569
490,sale price,5.679829527547868
491,consulting payments,5.6796996858959625
492,investee companies,5.676965669988926
493,prior period,5.6769568151147105
494,financing rounds,5.668432126532685
495,escrow period,5.664277389277389
496,proposed valuations,5.655612650917441
497,cash distributions,5.651632770183262
498,unobservable inputs,5.651587301587302
499,investment company subsidiaries,5.647800430388267
500,liquidation preferences,5.642948390393459
501,market multiples,5.635461548505027
502,interest method,5.6218442499407875
503,undisclosed buyer,5.619047619047619
504,underlying securities,5.618386652906777
505,period presentation,5.599051878354204
506,payments,5.598471615720524
507,common shares,5.598267614860057
508,loan,5.591502331815037
509,marketable assets,5.588204088001248
510,portfolio investments,5.585511378636676
511,early adoption,5.580025113493673
512,stock plan&quot,5.578510043704825
513,revenue code,5.5633292383292385
514,portfolio companies,5.5417099652416955
515,investments,5.537527858840333
516,fasb issued asu,5.535265700483092
517,important assumptions,5.527811518114378
518,multiple sources,5.52713839158852
519,exit opportunities,5.525
520,valuation procedures,5.519896432093086
521,bridge,5.519843990344454
522,portfolio companies,5.519098059381059
523,undx consortium,5.517647058823529
524,foreign currency,5.508647798742138
525,december31,5.504541191533513
526,fair values,5.499668865737792
527,sale price,5.475489563714234
528,valuation procedures&quot,5.47156976759438
529,milestone payments,5.468172230529398
530,impactful returns,5.461538461538462
531,valuation committee,5.459967320261438
532,assumptions,5.455365697680941
533,company harris,5.438563900095399
534,active portfolio&quot,5.434620611573867
535,quoted prices,5.409198445774448
536,greater returns,5.40856134157105
537,discount factors,5.399743448781382
538,average holdings,5.391734921816828
539,input assumptions,5.380600516068496
540,management,5.377691977691978
541,sec certification,5.375548801080717
542,portfolio investment valuations,5.373968642828538
543,cash flows,5.373059561818782
544,effective yield,5.343764609630668
545,series,5.340031397174254
546,convertible debt,5.3242290748898675
547,portfolio companies,5.314437237968969
548,amendment date,5.313341503267973
549,enumeral owned,5.311831789023522
550,section,5.311401457846238
551,escrow payment,5.295222446916077
552,publicly traded,5.2942905495680055
553,traded publicly,5.2942905495680055
554,judgment,5.2785714285714285
555,equity securities,5.275489459811389
556,initial investments,5.256845566175021
557,securities equity,5.255209739531669
558,repurchase program,5.248594604791549
559,cash expense,5.2479487756627154
560,business development company,5.247721433231723
561,investments,5.219016659894352
562,equity method investment,5.200040469424463
563,liability values,5.196387176930244
564,taxable year,5.192193006234752
565,portfolio companies,5.192173787134089
566,management,5.191833391833391
567,net increases,5.190273613928338
568,thereto,5.1875
569,sector decrease,5.184834560945762
570,benefits,5.152100840336134
571,income securities,5.127291268616199
572,venture debt,5.126638713444084
573,proceeds,5.126543487444111
574,management fees,5.123557886244454
575,adesto technologies,5.113112693757855
576,adesto technologies,5.113112693757855
577,financial statements,5.10760904968306
578,portfolio company investments,5.105424485081281
579,year beginning,5.1010685061202405
580,equity method investments,5.07551763146211
581,equity method,5.07499578507471
582,accounting policies,5.0577922077922075
583,consolidation guidance,5.052606255012028
584,dollar amount,5.047265103868877
585,pricing models,5.016631028747922
586,deemed dividends&quot,5.014253507757112
587,accompanying notes,5.004915730337078
588,public exchanges,4.974734042553191
589,forfeiture rate,4.973544973544973
590,accounting standards,4.9714285714285715
591,share liquidation preferences,4.951192117992026
592,share award terms,4.9288608383980055
593,biomedical applications,4.925531914893617
594,differences,4.923310023310023
595,independent members,4.912698412698413
596,option premiums,4.880298507462687
597,diversification,4.873563218390805
598,debt expense,4.873511371540586
599,current environment,4.8711886304909555
600,share classes,4.867861645912137
601,consolidated statements,4.8651728694120235
602,factors&quot,4.862312731446588
603,patient partner,4.857142857142858
604,machine learning,4.857142857142857
605,owned subsidiaries,4.857049180327869
606,internal models,4.847988077496274
607,privately held,4.837451539072353
608,20 privately held,4.837451539072353
609,21 privately held,4.837451539072353
610,22 privately held,4.837451539072353
611,23 privately held,4.837451539072353
612,28 privately held,4.837451539072353
613,market environment,4.830630630630631
614,services,4.825490196078432
615,future environment,4.810273590173088
616,modified retrospective,4.805555555555555
617,exemptive order,4.8
618,insurance expense,4.796650717703349
619,bridge notes,4.794642857142858
620,meetings,4.791881918819188
621,currency fluctuations,4.791666666666666
622,fair values,4.789991446382954
623,local taxes,4.781818181818181
624,space,4.777777777777778
625,option,4.773631840796019
626,binomial model,4.769230769230769
627,lattice model,4.769230769230769
628,debt holders,4.738514789175582
629,public offering,4.731678486997636
630,market capitalization,4.731640731640732
631,performance target,4.730392156862745
632,pricing model,4.725752508361204
633,providing strategic,4.7254901960784315
634,financial condition,4.725427194391704
635,digital technologies,4.723502304147465
636,diversification requirements,4.719717064544651
637,payment,4.718130740668361
638,tax,4.717821782178218
639,precision medicine,4.7106261859582546
640,interest rates,4.698098794771686
641,capital,4.690989847715736
642,outstanding debt,4.681636482297275
643,debt,4.681636482297275
644,financial instrument,4.676646706586826
645,financial highlights,4.676646706586826
646,cobalt technologies,4.671554252199414
647,venture capital,4.668399486269953
648,compensation expense,4.663798425682976
649,precision health,4.662958843159066
650,secured creditor,4.661538461538461
651,financial performance,4.657038863449571
652,option holders,4.654584221748401
653,remaining capacity,4.653333333333333
654,foreign companies,4.651089659207255
655,global environment,4.644444444444444
656,open market,4.640731640731641
657,option,4.640298507462687
658,statements,4.630962343096234
659,volatility,4.625
660,tax obligation,4.617821782178218
661,based awards,4.617267585719335
662,actively traded,4.614678899082569
663,general office,4.612938596491228
664,unrealized depreciation,4.612580943570768
665,000 remains outstanding,4.601851851851852
666,income,4.599481865284973
667,laird technologies,4.580645161290322
668,biochemical technologies,4.580645161290322
669,unrealized appreciation,4.58036750483559
670,security holdings,4.579336349924585
671,fee income,4.574481865284974
672,corporate bonds,4.574468085106383
673,liquidity events,4.567438386855862
674,base rent,4.565476190476191
675,escrow,4.56457977842407
676,compensation committee,4.564516129032258
677,net income,4.563439462458119
678,health care,4.5615763546798025
679,interest,4.555656934306569
680,freely tradeable,4.555555555555555
681,round led,4.546153846153846
682,secondary liquidity,4.542860525692635
683,gross income,4.539907397199867
684,expense,4.5397584871269085
685,statements,4.53603480686435
686,average price,4.531141480900638
687,indemnity claims,4.529411764705882
688,additional certifications,4.528169014084507
689,income taxes,4.526754592557701
690,business,4.526315789473684
691,fee payments,4.523471615720524
692,market quotations,4.51951951951952
693,similar businesses,4.513131313131312
694,eligibility requirements,4.512820512820513
695,deferred rent,4.51047619047619
696,medicine market,4.509715597950892
697,free rate,4.5092592592592595
698,cash holdings,4.502850833166031
699,combination,4.5
700,financial position,4.4971595270996465
701,estimated rate,4.4936342592592595
702,interim periods,4.491532783326097
703,merton option,4.487917555081734
704,current rate,4.486003445305771
705,large funds,4.479591836734694
706,operating commitment,4.478982637831252
707,operating commitment,4.478982637831252
708,operating commitment,4.478982637831252
709,employee members,4.477624784853701
710,customary exclusions,4.473684210526316
711,public market,4.473420228739378
712,regulatory requirements,4.469342251950947
713,debt expenses,4.465718436591995
714,data communications,4.464516129032258
715,respective location,4.458333333333334
716,classification,4.458333333333333
717,financial assets,4.449466179203459
718,perform interim,4.448979591836735
719,insurance contract,4.447368421052632
720,dental insurance,4.447368421052632
721,expense recognition,4.440191387559809
722,gains,4.437434279705573
723,gains,4.437434279705573
724,call options,4.434782608695652
725,original plan,4.43125
726,existing portfolio,4.4305679452869455
727,proposed modifications,4.428571428571429
728,net basis,4.42806016127571
729,current expectations,4.426744186046512
730,similar expressions,4.4222222222222225
731,life sciences,4.420303605313093
732,based compensation,4.419588592800373
733,premiums,4.418723404255319
734,income tax,4.417303647463192
735,comprehensive income,4.4168731696328
736,remaining life,4.416774193548386
737,preferred stock,4.416666666666667
738,current market,4.412930372232697
739,consolidated schedule,4.409938681655595
740,backed debt,4.406582016066338
741,medical benefit,4.4
742,positive contributions,4.4
743,meaningful growth,4.4
744,undx consortium,4.4
745,employee directors,4.398934613132838
746,annual basis,4.397435897435898
747,york corporation,4.3917116544934895
748,investment series,4.389383922583118
749,stock compensation,4.386738351254481
750,gross returns,4.385880077369439
751,deferred gain,4.381643835616439
752,financial instruments,4.376646706586826
753,utilization fee,4.375
754,unconsolidated entities,4.375
755,corporate structure,4.36613475177305
756,option,4.36337543053961
757,significant subsidiary,4.359523809523809
758,fully vested,4.357142857142858
759,sec,4.357142857142858
760,categorized based,4.355072463768115
761,subsequent events,4.353846153846154
762,national exchange,4.351851851851852
763,disruptive science,4.349537037037037
764,current employee,4.347226113757355
765,historical facts,4.344827586206897
766,historical fluctuations,4.344827586206897
767,debt security,4.344741895402688
768,private security,4.342251950947603
769,expenses,4.341489361702127
770,annual letter,4.333333333333334
771,options,4.333333333333334
772,increased levels,4.333333333333334
773,annual assessments,4.333333333333334
774,deemed worthless,4.333333333333333
775,secondary sector,4.329268292682927
776,employment taxes,4.327272727272727
777,appropriately represent,4.325
778,regenerative medicine,4.3235294117647065
779,diversification strategy,4.3180076628352495
780,future payments,4.314300761449168
781,negative covenants,4.3125
782,remaining amounts,4.312063492063492
783,unamortized fees,4.310945273631841
784,professional fees,4.310945273631841
785,custody fees,4.310945273631841
786,financing charges,4.309124767225326
787,expenses,4.307686544800719
788,stock,4.306597222222223
789,senior associate,4.306451612903226
790,income approach,4.304745023179711
791,income,4.30455432905309
792,financial institutions,4.301646706586826
793,outstanding principal,4.300264550264551
794,primary liquidity,4.294337574624615
795,market approach,4.291449344080923
796,current portfolio,4.288891078701878
797,financial liability,4.288587005094289
798,public listings,4.287234042553191
799,public equities,4.287234042553191
800,bankers,4.285714285714286
801,preventative care,4.285714285714286
802,interest expense,4.279939230957288
803,multiple sectors,4.277777777777778
804,fees,4.277611940298508
805,expenses,4.274822695035461
806,party,4.2727272727272725
807,stock,4.264104141041411
808,underlying principle,4.2631578947368425
809,unaffiliated companies,4.256689172293074
810,necessarily represent,4.255232558139535
811,prices,4.254559270516717
812,based payments,4.253544079488639
813,additional operating,4.252049611099432
814,valuation purposes,4.251633986928105
815,expected payments,4.251412792191113
816,audit committee,4.25
817,total operating,4.24913312226745
818,respective markets,4.248456790123457
819,compensation cost,4.247477022887007
820,exit environment,4.2444444444444445
821,consulting income,4.239481865284974
822,presently estimated,4.234375
823,unrealized losses,4.23080040526849
824,net,4.230624263839811
825,volatility,4.227941176470589
826,accrued expenses,4.227203647416413
827,current status,4.226744186046512
828,high policy,4.225609756097561
829,1940 act&quot,4.225037821482602
830,plan prior,4.224232456140351
831,operating activities,4.223880597014926
832,public companies,4.221342569684975
833,annual report,4.21969696969697
834,tax,4.217821782178218
835,tax authorities,4.217821782178218
836,foreign currencies,4.216981132075471
837,accrued interest,4.216371220020855
838,aggregate operating,4.21470628508832
839,historical information,4.213986464711569
840,daily liquidity,4.213592233009709
841,adequate liquidity,4.213592233009709
842,future periods,4.208382337218005
843,private financings,4.2059496567505725
844,net asset,4.200914118912275
845,life,4.199715370018975
846,taxable income,4.199481865284974
847,similar assets,4.195041694838855
848,fully exercise,4.193548387096774
849,significant inter,4.192857142857143
850,significant developments,4.192857142857143
851,options,4.191881918819188
852,credit,4.190476190476191
853,market participants,4.186186186186186
854,market quotation,4.186186186186186
855,market inefficiencies,4.186186186186186
856,otc market,4.186186186186186
857,market comparables,4.186186186186186
858,market movements,4.186186186186186
859,growing market,4.186186186186186
860,amounts,4.18394541088268
861,general restriction,4.175438596491228
862,general supervision,4.175438596491228
863,general economy,4.175438596491228
864,debt investment,4.17211639883353
865,funds,4.171473755553882
866,accrued benefits,4.171428571428571
867,accounting retrospectively,4.171428571428571
868,capital,4.170090794087976
869,previously authorized,4.168181818181818
870,portfolio,4.167219356423483
871,sufficient competition,4.166666666666667
872,economic downturn,4.166666666666666
873,future quarters,4.165829145728644
874,future growth,4.165829145728644
875,foreseeable future,4.165829145728644
876,gain,4.165744781988678
877,expenses,4.1653699587170525
878,operating expenses,4.1653699587170525
879,future amounts,4.157892637792136
880,outstanding options,4.157407407407407
881,amendments,4.15625
882,milestone payments,4.154218742157306
883,income,4.154027319830428
884,fiscal periods,4.153664302600473
885,tax cost,4.150782676032967
886,merton model,4.15018315018315
887,premiums,4.150059171597633
888,future performance,4.146221302591389
889,guidelines,4.145833333333333
890,financing,4.14245810055866
891,income,4.142339008142117
892,interim period,4.141287284144427
893,statements,4.141021514693867
894,recent developments,4.138888888888889
895,recent arm,4.138888888888889
896,potential liquidity,4.1385922330097085
897,net assets,4.136777069789778
898,liquid market,4.133554607238818
899,common stock,4.131481481481481
900,interest income,4.130138799591544
901,debt securities,4.129457833059803
902,payments,4.127195019975844
903,applicable income,4.1254077912108995
904,specific identification,4.125
905,fee,4.125
906,senova systems,4.125
907,specific facts,4.125
908,discount rate,4.122004357298475
909,oncology,4.121293199554069
910,employee headcount,4.120481927710843
911,employee turnover,4.120481927710843
912,subsequently marked,4.117647058823529
913,subsequently amortize,4.117647058823529
914,loan facility,4.116464510332435
915,loan facility,4.116464510332435
916,capital resources,4.113608895334783
917,subjective factors,4.1117647058823525
918,good faith,4.111111111111111
919,previously reported,4.109259259259259
920,net cash,4.107984900927411
921,initial preference,4.10752688172043
922,total primary,4.1059978668674315
923,hybrid approach,4.105263157894736
924,hybrid approach,4.105263157894736
925,agency securities,4.105228758169934
926,entirety,4.105072463768115
927,stock plan,4.103472222222223
928,additional capital,4.094158861800243
929,cash expense,4.093309600404984
930,proposed valuations,4.092505854800937
931,exercise price,4.091778475592349
932,private transactions,4.091631603553062
933,cobalt biofuels,4.090909090909091
934,independent milestones,4.090643274853801
935,harris group,4.087768440709617
936,total portfolio,4.087399417907893
937,market price,4.084416274681761
938,capital,4.0841716658975535
939,focused portfolio,4.08388602309015
940,active market,4.083622083622084
941,full retrospective,4.081196581196581
942,corporation&quot,4.079515433422901
943,public markets,4.077357499343314
944,venture investors,4.076768612913192
945,liquidity discount,4.076337331048924
946,stock options,4.072222222222223
947,treasury stock,4.072222222222223
948,comprehensive loss,4.071049840933192
949,information,4.069158878504673
950,microcapitalization companies,4.067441860465117
951,pension obligation,4.066666666666666
952,values,4.066265060240964
953,capital,4.065989847715736
954,contributed capital,4.065989847715736
955,working capital,4.065989847715736
956,borrowed capital,4.065989847715736
957,accrual basis,4.064102564102564
958,future price,4.064059234224219
959,net settlement,4.063957597173145
960,forfeiture estimate,4.06312292358804
961,loan facilities,4.062893081761006
962,larger portfolio,4.062146892655367
963,relative seniority,4.0588235294117645
964,business plan,4.057565789473684
965,credit facility,4.053571428571429
966,vested forfeitures,4.049450549450549
967,payments,4.0484716157205245
968,future distributions,4.048182086905114
969,merton formula,4.0476190476190474
970,merton equations,4.0476190476190474
971,debt investments,4.047593560871176
972,present unrealized,4.046276595744681
973,ultimate returns,4.045454545454545
974,harris partners,4.0436507936507935
975,subsequent periods,4.042553191489361
976,primary industry,4.039649451203948
977,based companies,4.039180990899899
978,cost approach,4.038224051749485
979,materials science,4.037037037037037
980,share purchase agreement,4.036448855803695
981,term income,4.032815198618307
982,participants,4.03125
983,interest,4.0306569343065695
984,financial liabilities,4.030094982448896
985,performance condition,4.029172644667623
986,additional indebtedness,4.028169014084507
987,primary methodology,4.028113762667538
988,similar securities,4.027450980392157
989,semiconductor business,4.026315789473684
990,business activities,4.026315789473684
991,business activity,4.026315789473684
992,synthesis business,4.026315789473684
993,business strategies,4.026315789473684
994,business foci,4.026315789473684
995,rounds,4.025974025974026
996,period,4.0256410256410255
997,agreement,4.025174825174825
998,company consolidates,4.019913106444605
999,ready market,4.01951951951952
1000,related problems,4.018181818181818
1001,related sectors,4.018181818181818
1002,multiple rounds,4.018037518037518
1003,senior preferences,4.015189476980896
1004,relevant inputs,4.014285714285714
1005,liquid capital,4.013358268768368
1006,molecular imprints,4.011173184357542
1007,related amounts,4.01024531024531
1008,amounts,4.01024531024531
1009,employee benefits,4.006196213425129
1010,month period,4.0048076923076925
1011,valuation committee,4.001633986928105
1012,valuation policy,4.001633986928105
1013,internally managed,4.0
1014,united states,4.0
1015,raw materials,4.0
1016,advanced materials,4.0
1017,magic leap,4.0
1018,parallel universes,4.0
1019,undisclosed buyer,4.0
1020,geo semiconductor,4.0
1021,broad categories,4.0
1022,continued appropriateness,4.0
1023,administrative agent,4.0
1024,options,4.0
1025,deduction,4.0
1026,square foot,4.0
1027,north carolina,4.0
1028,balance sheet,4.0
1029,direct deduction,4.0
1030,inherently illiquid,4.0
1031,assign probabilities,4.0
1032,fully expensed,4.0
1033,principally engaged,4.0
1034,contractual arrangements,4.0
1035,emerging fields,4.0
1036,partially exited,4.0
1037,1 bank,4.0
1038,symbols,4.0
1039,corden pharmaceuticals,4.0
1040,road show,4.0
1041,larger percentages,4.0
1042,fully exited,4.0
1043,successfully executing,4.0
1044,biosystems,4.0
1045,bdcs,4.0
1046,frequent communication,4.0
1047,products,4.0
1048,resource constraints,4.0
1049,thomson reuters,4.0
1050,lifetime,4.0
1051,fractured syndicates,4.0
1052,fractured syndicate,4.0
1053,intensive sectors,4.0
1054,global economy,4.0
1055,protection,4.0
1056,strategic opportunities,4.0
1057,subjective judgments,4.0
1058,credit spreads,4.0
1059,broader array,4.0
1060,ngx bio,4.0
1061,ohso clean,4.0
1062,contractual obligations,4.0
1063,conventional channels,4.0
1064,credit arrangements,4.0
1065,substantial doubt,4.0
1066,practical expedients,4.0
1067,pari passu,4.0
1068,actively engaged,4.0
1069,returns,4.0
1070,labs,4.0
1071,consummated arm,4.0
1072,netting arrangements,4.0
1073,genome profiling,4.0
1074,undiagnosed diseases,4.0
1075,nano terra,4.0
1076,mend protocol,4.0
1077,trade publicly,3.997793468667255
1078,cost basis,3.9970634579573128
1079,financial results,3.9969592065868262
1080,dividend date,3.996874111963626
1081,valuation procedures,3.996531946111778
1082,financing events,3.996304254404813
1083,portfolio companies,3.9962554197871505
1084,discussed previously,3.9951612903225806
1085,historical investment,3.9927149101505583
1086,term appreciation,3.992424242424242
1087,amounts,3.992063492063492
1088,amounts,3.992063492063492
1089,net proceeds,3.991864573917331
1090,early adoption,3.9917898193760264
1091,aggregate intrinsic,3.9908256880733948
1092,financial rights,3.990600194958919
1093,accounting fees,3.982373845060412
1094,securities,3.9822779384978038
1095,performance,3.980392156862745
1096,funds,3.979591836734694
1097,preferred equity,3.976243607624361
1098,high volumes,3.975609756097561
1099,high weighting,3.975609756097561
1100,biovex group,3.9746732026143787
1101,public financings,3.971444568868981
1102,current cash,3.9707714898007778
1103,potential returns,3.9704545454545457
1104,stock price,3.9704523107177976
1105,similar sources,3.965700483091787
1106,provide medical,3.963106796116505
1107,indemnity escrow,3.9612745098039217
1108,mersana therapeutics,3.9607843137254903
1109,expenses,3.9596711798839457
1110,related expenses,3.9596711798839457
1111,industry sectors,3.9589041095890414
1112,loss,3.9577594829576057
1113,focused companies,3.955847657566566
1114,exit events,3.953846153846154
1115,individuals,3.95
1116,individuals,3.95
1117,income,3.949481865284974
1118,net impact,3.9433968495095932
1119,address problems,3.942857142857143
1120,profits,3.942857142857143
1121,repurchase program,3.9403508771929827
1122,updated analysis,3.9391304347826086
1123,expected term,3.936274509803922
1124,transactions,3.936089656216871
1125,cash,3.9359092225734544
1126,liquidation preference,3.9342105263157894
1127,liquidation,3.9342105263157894
1128,comparable companies,3.934108527131783
1129,companies,3.934108527131783
1130,companies,3.934108527131783
1131,companies,3.934108527131783
1132,companies,3.934108527131783
1133,exited companies,3.934108527131783
1134,companies,3.934108527131783
1135,weak companies,3.934108527131783
1136,risky companies,3.934108527131783
1137,ourportfolio companies,3.934108527131783
1138,prior rounds,3.933242196400091
1139,cost,3.932960893854749
1140,profit interest,3.9306569343065694
1141,interest,3.9306569343065694
1142,interest,3.9306569343065694
1143,necessarily indicative,3.9302325581395348
1144,rent,3.9263252470799643
1145,applicable regulations,3.9259259259259256
1146,investment pace,3.9256651017214397
1147,greater volatility,3.925
1148,potential growth,3.925
1149,aggregate cost,3.9237865819281432
1150,remains difficult,3.922705314009662
1151,current period,3.919051878354204
1152,amp,3.9186507936507935
1153,amp,3.9186507936507935
1154,amp,3.9186507936507935
1155,amp,3.9186507936507935
1156,amp,3.9186507936507935
1157,amp,3.9186507936507935
1158,amp,3.9186507936507935
1159,amp,3.9186507936507935
1160,amp,3.9186507936507935
1161,amp,3.9186507936507935
1162,amp,3.9186507936507935
1163,amp,3.9186507936507935
1164,amp,3.9186507936507935
1165,amp,3.9186507936507935
1166,amp,3.9186507936507935
1167,amp,3.9186507936507935
1168,amp,3.9186507936507935
1169,amp,3.9186507936507935
1170,amp,3.9186507936507935
1171,amp,3.9186507936507935
1172,amp,3.9186507936507935
1173,amp,3.9186507936507935
1174,amp,3.9186507936507935
1175,amp,3.9186507936507935
1176,amp,3.9186507936507935
1177,amp,3.9186507936507935
1178,amp,3.9186507936507935
1179,amp,3.9186507936507935
1180,amp,3.9186507936507935
1181,amp,3.9186507936507935
1182,amp,3.9186507936507935
1183,amp,3.9186507936507935
1184,amp,3.9186507936507935
1185,amp,3.9186507936507935
1186,fasb clarified,3.9130434782608696
1187,fasb voted,3.9130434782608696
1188,loss,3.91248206599713
1189,values,3.91241890639481
1190,invested capital,3.9089650543273065
1191,electronics portfolio,3.9083007388092135
1192,funds,3.904825481594507
1193,investment commitment,3.9029893647599887
1194,investment commitment,3.9029893647599887
1195,investment commitment,3.9029893647599887
1196,strike price,3.898230088495575
1197,additional information,3.89732789258918
1198,substantially relative,3.895187165775401
1199,complex models,3.8934426229508197
1200,existing investments,3.8917855386128872
1201,main drivers,3.888888888888889
1202,real drivers,3.888888888888889
1203,deal team,3.888888888888889
1204,core benefits,3.8857142857142857
1205,additional detail,3.885311871227364
1206,single sector,3.8846153846153846
1207,portfolio day,3.882659713168188
1208,companies,3.8814769481844147
1209,asset,3.878623188405797
1210,risk,3.878451380552221
1211,securities,3.8779560308972076
1212,revenue recognition,3.8746928746928746
1213,cash flows,3.873059561818782
1214,securities,3.8683866529067767
1215,historical investments,3.868192072188205
1216,effectively settled,3.8666666666666667
1217,line basis,3.8641025641025646
1218,discount ratios,3.8627450980392157
1219,significant estimates,3.85952380952381
1220,companies,3.859342171991596
1221,derivatives,3.858548585485855
1222,current equity,3.858543349226428
1223,capital structure,3.857656514382403
1224,remaining milestones,3.8550877192982456
1225,rates,3.85254824344384
1226,otc exchange,3.851851851851852
1227,consulting fees,3.850945273631841
1228,fully diluted,3.85
1229,potentially dominant,3.85
1230,operating entities,3.8488805970149254
1231,investment income,3.847369189228636
1232,adjusted basis,3.846711259754738
1233,industrial biotechnology,3.8461538461538463
1234,differ significantly,3.8438133874239346
1235,remaining amount,3.842012578616352
1236,market conditions,3.84135859997929
1237,previously generally,3.841228070175439
1238,securities,3.8396037581699347
1239,prior round,3.839136302294197
1240,accounting estimates,3.838095238095238
1241,substantially reduced,3.8363636363636364
1242,substantially equivalent,3.8363636363636364
1243,section,3.8363636363636364
1244,amounts,3.8350386986750626
1245,periods,3.834219858156028
1246,consistent basis,3.8333333333333335
1247,prescribed guidelines,3.833333333333333
1248,term,3.833333333333333
1249,leasehold improvements,3.833333333333333
1250,accounts,3.833333333333333
1251,depository accounts,3.833333333333333
1252,technological improvements,3.833333333333333
1253,bank accounts,3.833333333333333
1254,term effects,3.833333333333333
1255,affects vesting,3.833333333333333
1256,interest,3.8306569343065693
1257,future valuations,3.8297635719581518
1258,ultimately realized,3.826323168594462
1259,business,3.826315789473684
1260,remaining years,3.823875968992248
1261,equity,3.8236810819991045
1262,position,3.8205128205128203
1263,leadership position,3.8205128205128203
1264,backed companies,3.816461468308254
1265,total yield,3.815575105897686
1266,readily marketable,3.8153846153846156
1267,payments,3.815138282387191
1268,ordinary income,3.8148664806695893
1269,assets,3.814486139283299
1270,future round,3.8119829918824895
1271,utilization fees,3.810945273631841
1272,fees,3.810945273631841
1273,credit losses,3.8095238095238093
1274,wave systems,3.8068181818181817
1275,aggregate commitments,3.8056405028882097
1276,income securities,3.8047106234549086
1277,income securities,3.8047106234549086
1278,expense amortization,3.8038277511961724
1279,notice,3.8
1280,official notice,3.8
1281,license agreements,3.8
1282,stage classifications,3.8
1283,agreements,3.8
1284,total assets,3.798071997869158
1285,remaining investors,3.7943589743589743
1286,based approaches,3.7925724637681157
1287,cash resources,3.7916463513733136
1288,accumulated depreciation,3.791304347826087
1289,projected markets,3.7901234567901234
1290,markets,3.7901234567901234
1291,exciting markets,3.7901234567901234
1292,gas markets,3.7901234567901234
1293,fees,3.78966867788716
1294,outstanding equity,3.7892065705873237
1295,address electronics,3.789010989010989
1296,york,3.7872340425531914
1297,york city,3.7872340425531914
1298,expected financings,3.7871517027863777
1299,payment,3.786267995570321
1300,sec,3.7857142857142856
1301,recent round,3.785042735042735
1302,award,3.7804981004643308
1303,chart,3.778656126482214
1304,credit risk,3.7755102040816326
1305,risk,3.7755102040816326
1306,related industries,3.774279379157428
1307,ten years,3.7731067382230172
1308,comparable assets,3.772819472616633
1309,fixed assets,3.772819472616633
1310,significant impact,3.7722963951935915
1311,actively involved,3.769230769230769
1312,involved actively,3.769230769230769
1313,additional rounds,3.768428754344247
1314,service period,3.766381766381766
1315,future repurchases,3.7658291457286435
1316,additional paid,3.7640180706882806
1317,outstanding securities,3.762636165577342
1318,investment strategy,3.758998435054773
1319,rights offering,3.7583979328165373
1320,term potential,3.7583333333333333
1321,gas industries,3.7560975609756095
1322,performance risk,3.755902360944378
1323,initial investment,3.755414205664092
1324,initial investment,3.755414205664092
1325,market values,3.75245124642715
1326,valuation technique,3.7516339869281046
1327,implied valuation,3.7516339869281046
1328,valuation,3.7516339869281046
1329,methodof valuation,3.7516339869281046
1330,amounts,3.7513227513227516
1331,amounts,3.7513227513227516
1332,plan amendment,3.7512499999999998
1333,initial payment,3.7509377344336086
1334,considerable pressure,3.75
1335,continued pressure,3.75
1336,companies,3.746608527131783
1337,independent directors,3.745772946859903
1338,milestones,3.7456140350877196
1339,energy portfolio,3.7454802259887003
1340,cash equivalents,3.744027303754266
1341,cash monthly,3.744027303754266
1342,adjustment factor,3.7435897435897436
1343,stage investor,3.7411764705882353
1344,cautionary statement,3.7407407407407405
1345,agtech,3.736842105263158
1346,share purchases,3.7368151561699947
1347,factors,3.736764705882353
1348,primarily reflecting,3.735483870967742
1349,stage companies,3.734108527131783
1350,market volume,3.7316407316407316
1351,integral part,3.7299578059071727
1352,remaining maturity,3.729090909090909
1353,future date,3.7279206489966175
1354,subsequent year,3.725806451612903
1355,year deferral,3.725806451612903
1356,taxable year,3.725806451612903
1357,debt discounts,3.724229074889868
1358,shares,3.724175617109478
1359,prepayment,3.7241379310344827
1360,covenants,3.7241379310344827
1361,cash,3.7227507080095856
1362,closing price,3.721759500260281
1363,future success,3.721384701284199
1364,line method,3.7203539823008853
1365,amendment limits,3.7199999999999998
1366,undisclosed buyers,3.717948717948718
1367,management,3.7176850763807283
1368,impact,3.7173702868192073
1369,liability,3.717012762275578
1370,investor risk,3.7166866746698677
1371,intellectual property,3.7156177156177157
1372,investments,3.7152464048004967
1373,credit quality,3.7142857142857144
1374,significant increases,3.71092943201377
1375,semiconductors,3.710059171597633
1376,options,3.710059171597633
1377,investment portfolio,3.710034216599029
1378,portfolio investment,3.710034216599029
1379,amendments,3.7096153846153843
1380,future sources,3.7093074065982083
1381,preferences,3.70873786407767
1382,kind dividends,3.7058823529411766
1383,consulting agreement,3.701538461538462
1384,product development,3.701492537313433
1385,development,3.701492537313433
1386,product development,3.701492537313433
1387,current investors,3.701103160405486
1388,awarrant,3.7
1389,federal tax,3.6993032636596994
1390,valuation methodology,3.6990024079807364
1391,prior years,3.696858425132599
1392,investment returns,3.6933418693982074
1393,business prospects,3.692982456140351
1394,period,3.6923076923076925
1395,forfeitures,3.6923076923076925
1396,comparable period,3.6923076923076925
1397,active markets,3.6875593542260208
1398,main approaches,3.6875
1399,hybrid approaches,3.6875
1400,quarterly report,3.6863636363636365
1401,related innovations,3.6848484848484846
1402,related estimates,3.6848484848484846
1403,lower fair,3.6834038054968286
1404,energy consumption,3.6833333333333336
1405,net decreases,3.6797470708573554
1406,expenses,3.6773384183059012
1407,share,3.674440910697158
1408,resources,3.67357324609233
1409,shares,3.6721264367816095
1410,accounting records,3.6714285714285713
1411,accelerator,3.67
1412,accelerator,3.67
1413,accelerator,3.67
1414,liquidity event,3.6681376875551632
1415,portfolio securities,3.667375650825302
1416,commercial prospects,3.666666666666667
1417,presidential election,3.666666666666667
1418,term improvements,3.6666666666666665
1419,future circumstances,3.6658291457286434
1420,small differences,3.6655172413793102
1421,difficult market,3.6644470557514035
1422,increasing valuations,3.663934426229508
1423,definitive agreement,3.661538461538462
1424,agreement,3.661538461538462
1425,information,3.6608255451713396
1426,management resources,3.66023166023166
1427,lease,3.6577708006279437
1428,greater detail,3.6571428571428575
1429,additional proceeds,3.6560759908286933
1430,companies,3.6550387596899228
1431,actual results,3.6536458333333335
1432,transfers,3.6528688524590165
1433,escrow,3.651811594202899
1434,landlord payments,3.648471615720524
1435,investment categories,3.647887323943662
1436,investment adviser,3.647887323943662
1437,investment activities,3.647887323943662
1438,investment community,3.647887323943662
1439,investment portfolios,3.647887323943662
1440,investment partners,3.647887323943662
1441,investment manager,3.647887323943662
1442,reasons,3.645161290322581
1443,voting securities,3.643690296631473
1444,liquidation preferences,3.6429483903934594
1445,future sales,3.6427522226517204
1446,financing activity,3.642458100558659
1447,financing activities,3.642458100558659
1448,additional factors,3.63993371996686
1449,specific inputs,3.6392857142857142
1450,additional certification,3.639280125195618
1451,unaffiliated rights,3.6365341335333836
1452,closing fees,3.6344746853965466
1453,owned historically,3.6334594367381254
1454,initial investments,3.6308913677017385
1455,biology+ companies,3.6297607010448267
1456,additional repurchases,3.628169014084507
1457,valued based,3.6279151033620245
1458,present,3.625
1459,tables,3.625
1460,primary sources,3.624223602484472
1461,related securities,3.623410576351753
1462,asu revises,3.6222222222222222
1463,market,3.620968794881838
1464,valuation information,3.6207928654327777
1465,company,3.6199131064446055
1466,company,3.6199131064446055
1467,purchased shares,3.619853709508882
1468,based inputs,3.61935817805383
1469,execution,3.618181818181818
1470,subsequently closed,3.6176470588235294
1471,fiscal years,3.6149870801033592
1472,gross write,3.614010437575271
1473,significant effect,3.60952380952381
1474,guidance,3.609195402298851
1475,returns,3.6085613415710505
1476,operations,3.607655502392345
1477,proceeds,3.6066303809995053
1478,proceeds,3.6066303809995053
1479,treasury securities,3.6052287581699347
1480,securities,3.6052287581699347
1481,dollars,3.6050724637681157
1482,companies,3.60077519379845
1483,exit outcomes,3.6
1484,exit assumption,3.6
1485,interest accrue,3.597323600973236
1486,estimated time,3.5929407370517925
1487,multiples,3.59190031152648
1488,quantitative information,3.5913811007268954
1489,expense,3.589282296650718
1490,bridge note,3.589187056037885
1491,legal fees,3.5887230514096187
1492,money options,3.5882352941176467
1493,portfolio investments,3.5855113786366757
1494,valuation guidelines,3.5849673202614376
1495,adversely affect,3.5846153846153843
1496,affect negatively,3.5846153846153843
1497,speculative nature,3.583333333333333
1498,specialized nature,3.583333333333333
1499,interdisciplinary nature,3.583333333333333
1500,portfolio company,3.5820599990999726
1501,investment companies,3.581995851075445
1502,initial investors,3.5818858560794045
1503,restricted shares,3.5815014367816094
1504,gaap requires,3.579220779220779
1505,greater risk,3.575510204081633
1506,common inputs,3.5735449735449736
1507,underlying share,3.5714016223354084
1508,transactions,3.5698924731182795
1509,participation agreements,3.569230769230769
1510,lease term,3.5680272108843534
1511,transaction/sale values,3.566265060240964
1512,100 percent,3.565144418423107
1513,81 *calculated based,3.564531923227575
1514,award shares,3.5645177411294355
1515,additional milestones,3.5632567333827527
1516,date,3.5620915032679736
1517,effective yield,3.5611559139784945
1518,net increase,3.5598759645200833
1519,aggregate values,3.5570907483143586
1520,biotechnology,3.5562130177514795
1521,nanoscale patterning,3.5555555555555554
1522,chronic disease,3.5555555555555554
1523,related milestones,3.553269537480064
1524,interim decrease,3.5530688111675897
1525,equity method,3.5521531454808013
1526,time,3.5515481931921435
1527,entity,3.5504112092598232
1528,rent abatements,3.547619047619048
1529,total amount,3.5472651038688774
1530,similar manner,3.547222222222222
1531,unadjusted volume,3.5454545454545454
1532,investments,3.545103616416091
1533,round price,3.5443839346494213
1534,operating results,3.5441930970149254
1535,principal measure,3.5428571428571427
1536,differ substantially,3.5422459893048126
1537,current employees,3.5418126791971964
1538,stage rounds,3.5402597402597404
1539,dividends,3.5392156862745097
1540,shares,3.5390083556007976
1541,notes,3.5355392156862746
1542,contractual milestones,3.5350877192982457
1543,dependent milestones,3.5350877192982457
1544,milestones,3.5350877192982457
1545,investee companies,3.5341085271317834
1546,capital,3.5323764023375848
1547,capital,3.5275283092541976
1548,full abatement,3.5256410256410255
1549,individual investments,3.5233644859813085
1550,investments,3.5233644859813085
1551,ariel investments,3.5233644859813085
1552,section,3.522077922077922
1553,amount,3.5220125786163523
1554,substantial amount,3.5220125786163523
1555,delaware company,3.5199131064446054
1556,company,3.5199131064446054
1557,company,3.5199131064446054
1558,company places,3.5199131064446054
1559,company,3.5199131064446054
1560,company,3.5199131064446054
1561,company,3.5199131064446054
1562,company,3.5199131064446054
1563,periodic follow,3.5190713101160864
1564,commission,3.5172413793103448
1565,initial focus,3.516617790811339
1566,qualitative inputs,3.5142857142857142
1567,potentially lead,3.513793103448276
1568,day period,3.5128205128205128
1569,net sale,3.512645643820375
1570,single present,3.5096153846153846
1571,significant decreases,3.5086466165413537
1572,period,3.5071225071225074
1573,accounting applied,3.5047619047619047
1574,shares,3.504533844189017
1575,outstanding shares,3.504533844189017
1576,potential impact,3.5044392523364487
1577,50 years,3.503875968992248
1578,45 years,3.503875968992248
1579,subsequent years,3.503875968992248
1580,taxable years,3.503875968992248
1581,sionyx converted,3.5032894736842106
1582,additional investors,3.5025279884434815
1583,canadian dollars,3.5
1584,closed options,3.5
1585,profitability,3.5
1586,sections,3.5
1587,began realizing,3.5
1588,began building,3.5
1589,varying stages,3.5
1590,symbol enum,3.5
1591,transitions,3.5
1592,financially support,3.5
1593,rule 10b,3.5
1594,opportunities,3.5
1595,company,3.4986365106999244
1596,company,3.4986365106999244
1597,company,3.4986365106999244
1598,exit price,3.4982300884955753
1599,healthcare costs,3.496774193548387
1600,higher prices,3.4932810750279955
1601,voting classes,3.493006993006993
1602,ultimately realize,3.4914529914529915
1603,generally coincides,3.4912280701754383
1604,primary focus,3.489836250705816
1605,estimated enterprise,3.484375
1606,ten times,3.4835164835164836
1607,sales milestone,3.4826702033598584
1608,table,3.479166666666667
1609,table,3.479166666666667
1610,time employee,3.4790476647626365
1611,valuation,3.478906714200832
1612,termination fees,3.4776119402985075
1613,front payment,3.4767441860465116
1614,general assignment,3.4754385964912284
1615,cleantech&quot,3.4750378214826023
1616,quot,3.4750378214826023
1617,investors,3.4743589743589745
1618,investors,3.4743589743589745
1619,interested investors,3.4743589743589745
1620,implied post,3.473684210526316
1621,increases,3.472617743702081
1622,net decrease,3.4680468165039997
1623,forfeited owing,3.466386554621849
1624,share outstanding,3.4656511350059738
1625,ipo market,3.4627819308670373
1626,investment commitments,3.462702138758477
1627,activities,3.4615384615384617
1628,expected time,3.4615069135223813
1629,unobservable inputs,3.458730158730159
1630,diverse set,3.458333333333333
1631,trade significantly,3.4561128526645764
1632,business risks,3.454887218045113
1633,increases,3.4535561601243687
1634,based shares,3.4521989005497247
1635,amounts,3.4515229515229517
1636,borrowing equal,3.4511784511784516
1637,full potential,3.4506410256410254
1638,revenue multiples,3.4504504504504503
1639,individuals,3.45
1640,cash dividends,3.449909656695443
1641,historically held,3.4482921752294446
1642,period,3.4423076923076925
1643,dividends,3.44173140954495
1644,funds,3.4411302982731553
1645,identical assets,3.4394861392832996
1646,securities,3.438562091503268
1647,expectations,3.4380952380952383
1648,building companies,3.434108527131783
1649,invested approximately $8,3.4338842975206614
1650,defines fair,3.4334038054968286
1651,applies fair,3.4334038054968286
1652,measuring fair,3.4334038054968286
1653,approximates fair,3.4334038054968286
1654,participation agreement,3.430769230769231
1655,business terms,3.429541595925297
1656,employee share,3.42872565530941
1657,made quarterly,3.425954198473282
1658,accomplishments,3.425233644859813
1659,approximately half,3.424242424242424
1660,premium,3.4231678486997636
1661,equity markets,3.4219226199700397
1662,investment assets,3.420706796560295
1663,detail,3.4202496532593623
1664,year period,3.4181141439205955
1665,dividends,3.41594152453881
1666,opgen,3.4149184149184153
1667,liquidity,3.409510600356647
1668,renamed series,3.4081632653061225
1669,single amount,3.406627963231737
1670,healthcare decisions,3.4
1671,contingent asset,3.3994565217391304
1672,individual level,3.3978494623655915
1673,sec certification,3.396825396825397
1674,valuation,3.3967952772506855
1675,material part,3.3966244725738397
1676,consistent definition,3.394230769230769
1677,risk factors,3.3872749099639856
1678,voting shares,3.3855879752431477
1679,pay federal,3.3814814814814813
1680,reduced access,3.375
1681,high level,3.3734592184631524
1682,remaining warrants,3.3718518518518517
1683,118 consisting primarily,3.3714285714285714
1684,817 consisting primarily,3.3714285714285714
1685,consisting primarily,3.3714285714285714
1686,596 consisting primarily,3.3714285714285714
1687,413 consisting primarily,3.3714285714285714
1688,substantial ownership,3.3692307692307693
1689,increasing ownership,3.3692307692307693
1690,ownership percentages,3.3692307692307693
1691,exchange commission,3.3690932311621964
1692,company,3.3628883130561755
1693,full term,3.3589743589743586
1694,time,3.3585657370517925
1695,time,3.3585657370517925
1696,time,3.3585657370517925
1697,securities,3.3552287581699347
1698,disclosures,3.354838709677419
1699,payment,3.3534700243108118
1700,company,3.353246439777939
1701,voting rights,3.352415026833631
1702,valuation techniques,3.3516339869281047
1703,adjusted values,3.3488737558931376
1704,values,3.3488737558931376
1705,shares,3.3471264367816094
1706,escrowed shares,3.3471264367816094
1707,unissued shares,3.3471264367816094
1708,lease liability,3.3466341760584832
1709,equity offerings,3.34608487746563
1710,money valuation,3.3398692810457513
1711,single point,3.339160839160839
1712,coming years,3.337209302325581
1713,contingent assets,3.335319472616633
1714,computer equipment,3.333333333333333
1715,applied retrospectively,3.333333333333333
1716,targets,3.333333333333333
1717,otisville biotech,3.333333333333333
1718,coming decade,3.333333333333333
1719,effective date,3.332924836601307
1720,proceeds,3.327906976744186
1721,values,3.3255243195002233
1722,judgment,3.3241379310344827
1723,outstanding borrowings,3.3240740740740744
1724,measurements,3.322463768115942
1725,ordinary dividends,3.3212669683257916
1726,electronics&quot,3.321191667636448
1727,observer rights,3.3139534883720927
1728,redemption rights,3.3139534883720927
1729,emptive rights,3.3139534883720927
1730,valuation date,3.313725490196078
1731,certification,3.311111111111111
1732,quot,3.3083711548159354
1733,share,3.3082437275985663
1734,stated cost,3.307960893854749
1735,ultimate return,3.3076923076923075
1736,lowest level,3.3069403714565007
1737,fiscal quarter,3.3065998329156225
1738,escrow period,3.300641025641026
1739,shareholders,3.3
1740,insured limit,3.3
1741,competitive advantage,3.3
1742,unregistered securities,3.2927287581699347
1743,asset classes,3.291501976284585
1744,receive approximately $400,3.290909090909091
1745,consolidation analysis,3.2891304347826087
1746,required date,3.2862294343024567
1747,alternative methods,3.2857142857142856
1748,fully exercisable,3.2857142857142856
1749,recognize revenue,3.2837837837837838
1750,amount,3.282882143833744
1751,limited partnership,3.28125
1752,management,3.2792792792792795
1753,equity round,3.2779530093337623
1754,ipo,3.276595744680851
1755,operations,3.2765550239234447
1756,explicit guidance,3.2758620689655173
1757,guidance,3.2758620689655173
1758,administration expenses,3.2748226950354606
1759,partial write,3.2735849056603774
1760,considered issued,3.2727272727272725
1761,primarily owing,3.2663865546218487
1762,owing primarily,3.2663865546218487
1763,significant portion,3.2632796780684106
1764,regular review,3.263157894736842
1765,settlement date,3.262091503267974
1766,sec&quot,3.260752107196888
1767,reconcile change,3.2586206896551726
1768,period values,3.2585727525486563
1769,operations,3.258373205741627
1770,operations,3.258373205741627
1771,amount,3.257861635220126
1772,company,3.255762163048379
1773,company,3.255762163048379
1774,company,3.255762163048379
1775,company,3.255762163048379
1776,company,3.255762163048379
1777,company,3.255762163048379
1778,milestone progress,3.2557471264367814
1779,payment,3.251744186046512
1780,valuation methodologies,3.2516339869281046
1781,full year,3.2514474772539286
1782,orderly transaction,3.25
1783,successful completion,3.25
1784,financing,3.248518706619265
1785,assets&quot,3.247857294099235
1786,material impact,3.2461059190031154
1787,quot,3.2442685907133715
1788,realize&quot,3.2442685907133715
1789,specific number,3.2426470588235294
1790,registration statement,3.2407407407407405
1791,achieved irrespective,3.238095238095238
1792,achieved successfully,3.238095238095238
1793,partial drawdown,3.238095238095238
1794,total pre,3.237373737373737
1795,equity securities,3.237027921349851
1796,quantitative inputs,3.2365079365079366
1797,potential shareholders,3.225
1798,pronounced issue,3.2222222222222223
1799,maturing companies,3.219822812846069
1800,investment transactions,3.2177797970619415
1801,board seat,3.2160493827160495
1802,smaller board,3.2160493827160495
1803,ability,3.215686274509804
1804,director seats,3.2142857142857144
1805,generally classify,3.2121583027335783
1806,potential pipeline,3.210714285714286
1807,originally structured,3.2105263157894735
1808,managing member,3.208333333333333
1809,constraints,3.2051282051282053
1810,simplified calculation,3.2
1811,considered include,3.1979609175870856
1812,quot,3.1959680540407414
1813,calendar quarter,3.1954887218045114
1814,directors,3.1902173913043477
1815,indirectly borne,3.1875
1816,company,3.186579773111272
1817,company,3.186579773111272
1818,fair valuation,3.185037792424933
1819,form model,3.184531315678857
1820,length financings,3.1842105263157894
1821,revenue standard,3.1837837837837837
1822,proceeds,3.1834625322997416
1823,unrestricted securities,3.1766573295985063
1824,securities transactions,3.175121231288214
1825,investment maturities,3.174203113417346
1826,fair statement,3.1741445462375695
1827,monetize assets,3.1728194726166326
1828,level,3.170668934982224
1829,greater ownership,3.1692307692307695
1830,investment company,3.1678004303882674
1831,defined price,3.1674608577263443
1832,interests,3.166666666666667
1833,amortization,3.164604626143088
1834,determining fair,3.160676532769556
1835,amount,3.158376214979989
1836,energy&quot,3.1583711548159354
1837,diluted share,3.1582437275985664
1838,invest opportunistically,3.1559633027522933
1839,invest growth,3.1559633027522933
1840,invest alongside,3.1559633027522933
1841,commonly invest,3.1559633027522933
1842,equity investments,3.1551636491612247
1843,resulted primarily,3.1500000000000004
1844,investments,3.149318684454591
1845,partial sale,3.14868804664723
1846,shareholder approval,3.146110056925996
1847,company,3.145867304917888
1848,methodologies,3.145161290322581
1849,accelerator&quot,3.1450378214826022
1850,sec,3.1428571428571432
1851,ups,3.142857142857143
1852,financing closed,3.142458100558659
1853,length financing,3.142458100558659
1854,government securities,3.1401124791001673
1855,company,3.1389607254922245
1856,investors,3.1358974358974363
1857,company,3.135297721829221
1858,limited investors,3.1306089743589745
1859,portfolio summary,3.1259766798894097
1860,transactions,3.1254480286738353
1861,valuations,3.1233938856889676
1862,technology companies,3.1232977163209723
1863,limited owing,3.122636554621849
1864,valuation adjustments,3.122004357298475
1865,uncertainties,3.1203555960793254
1866,investee company,3.1199131064446055
1867,principally comprised,3.119047619047619
1868,percent interest,3.1187521724018072
1869,normal number,3.1176470588235294
1870,partially offset,3.1166666666666667
1871,highly volatile,3.1153846153846154
1872,fair presentation,3.1134038054968287
1873,sold substantially,3.1129593810444876
1874,management support,3.1126126126126126
1875,return greater,3.1076923076923078
1876,differ materially,3.105882352941176
1877,liabilities,3.103448275862069
1878,amount,3.100959947037405
1879,invested historically,3.099385463021827
1880,time,3.0993064777925334
1881,date,3.0978057889822597
1882,fair valuations,3.097338231726337
1883,positions,3.096774193548387
1884,company values,3.086178166685569
1885,consideration,3.0858490566037737
1886,material effect,3.0833333333333335
1887,deep dilution,3.0795454545454546
1888,day operations,3.0788860262544473
1889,amortized cost,3.0758180367118912
1890,boy&quot,3.075037821482602
1891,accumulated post,3.0736842105263156
1892,share,3.067502986857826
1893,company,3.065367651899151
1894,managing directors,3.0652173913043477
1895,price,3.064896755162242
1896,downs,3.0638297872340425
1897,information technology,3.058348067693862
1898,investment series,3.0560505892497845
1899,leases,3.054263565891473
1900,full amount,3.047653604257378
1901,investments,3.046207125575217
1902,3 investment,3.0457367863092535
1903,2 investment,3.0457367863092535
1904,meet quarterly,3.038095238095238
1905,values,3.0326516148628127
1906,volatilities,3.032608695652174
1907,favorable terms,3.028225806451613
1908,decreases,3.025848645281844
1909,investment history,3.022887323943662
1910,legal restrictions,3.021680216802168
1911,pension liabilities,3.0201149425287355
1912,sales milestones,3.0120107962213227
1913,generally increases,3.009300359332065
1914,directors,3.008399209486166
1915,fund investments,3.0033644859813085
1916,equity ownership,3.0010299324106855
1917,responsible parties,3.0
1918,fair values,2.9996688657377923
1919,investments&quot,2.998402307463911
1920,entity,2.9931972789115644
1921,materially affect,2.9846153846153847
1922,2015 ended,2.9834710743801653
1923,sale classification,2.9820213799805635
1924,table,2.979166666666667
1925,interest,2.976111479761115
1926,nvca&quot,2.9750378214826023
1927,maturity date,2.971182412358883
1928,company,2.9643575508890496
1929,shares,2.9625110521662243
1930,fair valued,2.9562464450907373
1931,invest primarily,2.9559633027522936
1932,investments,2.95518266779949
1933,bdc&quot,2.953298691047819
1934,company,2.9517312882627875
1935,observable inputs,2.9490683229813666
1936,series,2.9466248037676612
1937,early repayment,2.944170771756979
1938,assistance,2.943396226415094
1939,access,2.9381067961165046
1940,ventures management,2.929279279279279
1941,level,2.9212139483469
1942,unrestricted shares,2.9185550082101805
1943,conversion event,2.916083916083916
1944,impactful event,2.916083916083916
1945,2 inputs,2.9121351766513057
1946,gaap&quot,2.9114014578462384
1947,ric&quot,2.9036092500540307
1948,values,2.899598393574297
1949,board,2.882716049382716
1950,synglyco entered,2.882205513784461
1951,securities,2.881824502850786
1952,trade date,2.880273321449792
1953,sec regulation,2.869047619047619
1954,entity,2.8649921507064366
1955,conversion terms,2.8647642679900747
1956,shareholders,2.863106796116505
1957,acquisition agreements,2.8617283950617285
1958,operations,2.8583732057416267
1959,10 investments,2.8566978193146415
1960,company,2.853246439777939
1961,shares,2.8471264367816094
1962,registered shares,2.8471264367816094
1963,table sets,2.8363095238095237
1964,synglyco negotiated,2.8345864661654137
1965,measure fair,2.833403805496829
1966,genomics,2.833333333333333
1967,recognize transfers,2.8278688524590163
1968,firm,2.8214285714285716
1969,interome,2.818548387096774
1970,estimates,2.8181818181818183
1971,weighted,2.8181818181818183
1972,effective january,2.8125
1973,disposition date,2.8120915032679736
1974,control,2.8072813938198555
1975,company,2.8056273921588915
1976,past years,2.803875968992248
1977,code&quot,2.800037821482602
1978,convertible,2.8
1979,exists,2.8
1980,trends,2.7948717948717947
1981,ventures&quot,2.7917044881492687
1982,shares,2.7915708812260536
1983,development,2.7858298867110234
1984,company,2.784064049840832
1985,78 percent,2.779004329004329
1986,19 percent,2.779004329004329
1987,17 percent,2.779004329004329
1988,95 percent,2.779004329004329
1989,16 percent,2.779004329004329
1990,80 percent,2.779004329004329
1991,79 percent,2.779004329004329
1992,81 percent,2.779004329004329
1993,86 percent,2.779004329004329
1994,50 percent,2.779004329004329
1995,90 percent,2.779004329004329
1996,holdings,2.7588235294117647
1997,warrants,2.7518518518518515
1998,ipo&quot,2.751633566163453
1999,fourth quarter,2.7510442773600667
2000,transaction,2.75
2001,management,2.7477477477477477
2002,full board,2.741690408357075
2003,situation,2.7412280701754383
2004,fund operations,2.7383732057416266
2005,operations&quot,2.733411027224229
2006,providing,2.7254901960784315
2007,acquisition agreement,2.72326685660019
2008,company variations,2.719913106444605
2009,approximately $140 million,2.715909090909091
2010,approximately $4 million,2.715909090909091
2011,bridgelux,2.7142857142857144
2012,present continue,2.7093373493975905
2013,measurement date,2.7091503267973858
2014,management,2.6977189955913357
2015,company matures,2.686579773111272
2016,asc 820&quot,2.675037821482602
2017,time employees,2.6736342302024774
2018,china,2.6666666666666665
2019,convert,2.6666666666666665
2020,amount,2.664869721473495
2021,secured,2.6615384615384614
2022,liabilities,2.6475659229208928
2023,generally expect,2.6382868937048505
2024,average,2.632911392405063
2025,pricing,2.6231884057971016
2026,applied prospectively,2.619047619047619
2027,traded,2.614678899082569
2028,trading,2.611111111111111
2029,corporation,2.6044776119402986
2030,venture,2.602409638554217
2031,ownership,2.6
2032,board representation,2.5910493827160495
2033,transaction,2.583333333333333
2034,technologies,2.5806451612903225
2035,granted,2.5714285714285716
2036,decrease,2.5704757739527038
2037,bdc subject,2.5664961636828645
2038,unfunded $1,2.5555555555555554
2039,level hierarchy,2.5493646138807433
2040,identify forward,2.5454545454545454
2041,phylagen,2.5357142857142856
2042,adesto,2.5324675324675323
2043,synglyco beginning,2.5273088381330684
2044,debt,2.5242290748898677
2045,factor,2.5128205128205128
2046,awards,2.5121951219512195
2047,directors,2.5027173913043477
2048,offers,2.5
2049,requirement,2.5
2050,subsidiaries,2.48
2051,bridgelux,2.4784366576819403
2052,program,2.473684210526316
2053,shares,2.466174055829228
2054,lesser extent,2.4447674418604652
2055,offering,2.4444444444444446
2056,option,2.4402985074626864
2057,notes,2.4375
2058,2014 notes,2.4375
2059,2015 notes,2.4375
2060,40 notes,2.4375
2061,dividend,2.4347826086956523
2062,call,2.4347826086956523
2063,consolidated,2.4342105263157894
2064,statements,2.430962343096234
2065,purchases,2.4285714285714284
2066,president,2.4285714285714284
2067,obligation,2.4
2068,retirement,2.393939393939394
2069,models,2.3934426229508197
2070,100 percent,2.388095238095238
2071,percent increase,2.3840136054421768
2072,owned,2.377049180327869
2073,owned 2,2.377049180327869
2074,complete,2.375
2075,warrants trade,2.3700336700336697
2076,decreased,2.3661971830985915
2077,net,2.363957597173145
2078,expired,2.3636363636363638
2079,concern uncertainties,2.361788617886179
2080,events,2.353846153846154
2081,expense,2.349282296650718
2082,2015 expense,2.349282296650718
2083,2016 expense,2.349282296650718
2084,resulting,2.3461538461538463
2085,533 resulting,2.3461538461538463
2086,preferred,2.3444444444444446
2087,quotations,2.3333333333333335
2088,reliable,2.3333333333333335
2089,increased,2.3333333333333335
2090,gains,2.3333333333333335
2091,laws,2.3333333333333335
2092,vary,2.3333333333333335
2093,annual,2.3333333333333335
2094,12 months,2.33030303030303
2095,months,2.33030303030303
2096,represent,2.325
2097,medicine,2.323529411764706
2098,deferred,2.32
2099,remaining 50,2.32
2100,remaining 17,2.32
2101,remaining $150,2.32
2102,remaining 316,2.32
2103,converted,2.3157894736842106
2104,compensation,2.314516129032258
2105,acquisition transaction,2.3117283950617287
2106,senior,2.306451612903226
2107,water,2.2941176470588234
2108,public,2.2872340425531914
2109,accreted,2.2857142857142856
2110,$0 accrued,2.2857142857142856
2111,multiple,2.2777777777777777
2112,pace,2.2777777777777777
2113,health,2.2758620689655173
2114,acquire pre,2.2692640692640693
2115,rate,2.259259259259259
2116,categorized,2.25
2117,modified,2.25
2118,committee,2.25
2119,lower,2.25
2120,procedures,2.2448979591836733
2121,estimated,2.234375
2122,restricted,2.234375
2123,current,2.2267441860465116
2124,operating,2.2238805970149254
2125,award,2.217391304347826
2126,comprehensive,2.217391304347826
2127,holders,2.2142857142857144
2128,liquidity,2.2135922330097086
2129,identified,2.210526315789474
2130,diversification,2.206896551724138
2131,realizations,2.2
2132,contained,2.2
2133,expectations,2.2
2134,meets,2.2
2135,income,2.199481865284974
2136,exercise,2.193548387096774
2137,significant,2.192857142857143
2138,held,2.1918819188191883
2139,held $20,2.1918819188191883
2140,held $17,2.1918819188191883
2141,depreciation,2.1913043478260867
2142,rent,2.1904761904761907
2143,market,2.186186186186186
2144,000 market,2.186186186186186
2145,claims,2.176470588235294
2146,general,2.175438596491228
2147,accounting,2.1714285714285713
2148,llc hzo,2.167964404894327
2149,subsidiary,2.1666666666666665
2150,future,2.1658291457286434
2151,appreciation,2.159090909090909
2152,outstanding,2.1574074074074074
2153,payments,2.148471615720524
2154,03 requires,2.142857142857143
2155,principal,2.142857142857143
2156,requires,2.142857142857143
2157,recent,2.138888888888889
2158,significantly,2.1379310344827585
2159,volatility,2.125
2160,amendments,2.125
2161,employee,2.1204819277108435
2162,strategy,2.111111111111111
2163,anticipate,2.111111111111111
2164,initial,2.10752688172043
2165,based,2.1050724637681157
2166,* based,2.1050724637681157
2167,*based,2.1050724637681157
2168,realized,2.1041009463722395
2169,expected,2.1029411764705883
2170,model,2.1025641025641026
2171,services,2.1
2172,potentially,2.1
2173,000 earned,2.1
2174,life,2.096774193548387
2175,costs,2.096774193548387
2176,adoption,2.0952380952380953
2177,businesses,2.090909090909091
2178,light,2.090909090909091
2179,recognition,2.090909090909091
2180,primary,2.080745341614907
2181,service,2.074074074074074
2182,stock,2.0722222222222224
2183,43 stock,2.0722222222222224
2184,capital,2.065989847715736
2185,data,2.064516129032258
2186,basis,2.0641025641025643
2187,portfolio,2.062146892655367
2188,gain,2.0616438356164384
2189,common,2.0592592592592593
2190,returns,2.0454545454545454
2191,group,2.0441176470588234
2192,relating,2.0434782608695654
2193,periods,2.0425531914893615
2194,consulting,2.04
2195,voting,2.0384615384615383
2196,science,2.037037037037037
2197,plan,2.03125
2198,champions,2.028985507246377
2199,additional $625,2.028169014084507
2200,additional $7,2.028169014084507
2201,additional $938,2.028169014084507
2202,additional 119,2.028169014084507
2203,additional $234,2.028169014084507
2204,additional 12,2.028169014084507
2205,additional $5,2.028169014084507
2206,additional 111,2.028169014084507
2207,business,2.026315789473684
2208,total,2.025252525252525
2209,focused,2.0217391304347827
2210,921 related,2.018181818181818
2211,related,2.018181818181818
2212,955 related,2.018181818181818
2213,040 related,2.018181818181818
2214,milestone,2.0057471264367814
2215,issued,2.0
2216,partners,2.0
2217,reduce,2.0
2218,normal,2.0
2219,define,2.0
2220,means,2.0
2221,options,2.0
2222,order,2.0
2223,products,2.0
2224,treatment,2.0
2225,basic,2.0
2226,credit,2.0
2227,reasonable,2.0
2228,levels,2.0
2229,back,2.0
2230,experience,2.0
2231,create,2.0
2232,enabled,2.0
2233,discuss,2.0
2234,growth,2.0
2235,substantial,2.0
2236,deal,2.0
2237,sector,2.0
2238,opportunities,2.0
2239,commonly,2.0
2240,funding,2.0
2241,raise,2.0
2242,obligations,2.0
2243,critical,2.0
2244,unadjusted,2.0
2245,benefit,2.0
2246,individual,2.0
2247,taxable,2.0
2248,continued,2.0
2249,licensing,2.0
2250,amounts,1.992063492063492
2251,aggregate,1.9908256880733946
2252,000 performance,1.9803921568627452
2253,performance,1.9803921568627452
2254,funds,1.9795918367346939
2255,received,1.9787234042553192
2256,schedule,1.9757281553398058
2257,unaudited,1.9752475247524752
2258,small,1.9655172413793103
2259,industry,1.9589041095890412
2260,regulatory,1.9565217391304348
2261,generate,1.9545454545454546
2262,black,1.9541284403669725
2263,buyer,1.9487179487179487
2264,mature,1.9473684210526316
2265,unobservable,1.9444444444444444
2266,generated,1.9428571428571428
2267,generated $2,1.9428571428571428
2268,address,1.9428571428571428
2269,expenses,1.9414893617021276
2270,investor,1.9411764705882353
2271,reflecting,1.935483870967742
2272,liquidation,1.9342105263157894
2273,companies,1.934108527131783
2274,cost,1.9329608938547487
2275,interest,1.9306569343065694
2276,biovex,1.9305555555555556
2277,necessarily,1.930232558139535
2278,applicable,1.9259259259259258
2279,include,1.925233644859813
2280,include 1,1.925233644859813
2281,include $300,1.925233644859813
2282,potential,1.925
2283,method,1.920353982300885
2284,2015 method,1.920353982300885
2285,assumptions,1.9183673469387754
2286,fasb,1.9130434782608696
2287,choose,1.9090909090909092
2288,shows,1.9090909090909092
2289,collect,1.9
2290,pay,1.9
2291,consortium,1.9
2292,price,1.8982300884955752
2293,active,1.8974358974358974
2294,early,1.896551724137931
2295,june30,1.8909774436090225
2296,team,1.8888888888888888
2297,report,1.8863636363636365
2298,benefits,1.8857142857142857
2299,single,1.8846153846153846
2300,backed,1.8823529411764706
2301,distributions,1.8823529411764706
2302,september30,1.876543209876543
2303,&amp,1.875
2304,chart,1.8695652173913044
2305,information,1.8691588785046729
2306,settled,1.8666666666666667
2307,discount,1.8627450980392157
2308,prices,1.8617021276595744
2309,detail,1.8571428571428572
2310,loss,1.853658536585366
2311,exchange,1.8518518518518519
2312,diluted,1.85
2313,electronics,1.8461538461538463
2314,biotechnology,1.8461538461538463
2315,invested,1.8429752066115703
2316,invested $1,1.8429752066115703
2317,asset,1.8369565217391304
2318,substantially,1.8363636363636364
2319,term,1.8333333333333333
2320,accounts,1.8333333333333333
2321,deemed,1.8333333333333333
2322,coming,1.8333333333333333
2323,improvements,1.8333333333333333
2324,guidelines,1.8333333333333333
2325,closing,1.8235294117647058
2326,shareholder,1.8235294117647058
2327,security,1.8205128205128205
2328,position,1.8205128205128205
2329,day,1.8205128205128205
2330,authorized,1.8181818181818181
2331,commitments,1.8148148148148149
2332,borrowing,1.8148148148148149
2333,build,1.8125
2334,fees,1.8109452736318408
2335,losses,1.8095238095238095
2336,declared,1.8
2337,quarterly,1.8
2338,greater,1.8
2339,agreements,1.8
2340,stage,1.8
2341,primarily,1.8
2342,2015 primarily,1.8
2343,demand,1.8
2344,line,1.8
2345,contracts,1.8
2346,2016 primarily,1.8
2347,presented,1.7916666666666667
2348,structure,1.7916666666666667
2349,yield,1.7903225806451613
2350,markets,1.7901234567901234
2351,york,1.7872340425531914
2352,sec,1.7857142857142858
2353,revenue,1.7837837837837838
2354,adjusted,1.7826086956521738
2355,derived,1.7826086956521738
2356,legal,1.7777777777777777
2357,risk,1.7755102040816326
2358,assets,1.7728194726166329
2359,effective,1.7708333333333333
2360,realize,1.7692307692307692
2361,withholding 17,1.7692307692307692
2362,withholding 21,1.7692307692307692
2363,involved,1.7692307692307692
2364,consistent,1.7692307692307692
2365,participation,1.7692307692307692
2366,withholding 13,1.7692307692307692
2367,includes,1.7608695652173914
2368,reported,1.7592592592592593
2369,industries,1.7560975609756098
2370,valuation,1.7516339869281046
2371,denominated,1.75
2372,distribution,1.75
2373,existed,1.75
2374,draw,1.75
2375,ranks,1.75
2376,pressure,1.75
2377,cash,1.7440273037542662
2378,provided,1.7407407407407407
2379,statement,1.7407407407407407
2380,rounds,1.7402597402597402
2381,analysis,1.7391304347826086
2382,input,1.7380952380952381
2383,agtech,1.736842105263158
2384,paid,1.7358490566037736
2385,paid $1,1.7358490566037736
2386,lease,1.7346938775510203
2387,part,1.729957805907173
2388,determining,1.7272727272727273
2389,exits,1.7272727272727273
2390,year,1.7258064516129032
2391,year,1.7258064516129032
2392,required,1.7241379310344827
2393,ultimately,1.7222222222222223
2394,quantitative,1.7222222222222223
2395,classify,1.7209302325581395
2396,amendment,1.72
2397,quality,1.7142857142857142
2398,offerings,1.7142857142857142
2399,including,1.7100591715976332
2400,including 1,1.7100591715976332
2401,preferences,1.7087378640776698
2402,differ,1.7058823529411764
2403,dividends,1.7058823529411764
2404,account,1.7058823529411764
2405,development,1.7014925373134329
2406,instruments,1.7
2407,differences,1.7
2408,receive $7,1.7
2409,settlement,1.7
2410,receive $625,1.7
2411,receive $126,1.7
2412,receive,1.7
2413,receive $5,1.7
2414,receive $234,1.7
2415,biology+,1.6956521739130435
2416,period,1.6923076923076923
2417,forfeitures,1.6923076923076923
2418,approaches,1.6875
2419,unregistered,1.6875
2420,lack,1.6857142857142857
2421,important,1.6842105263157894
2422,financings,1.6842105263157894
2423,energy,1.6833333333333333
2424,wave,1.6818181818181819
2425,presentation,1.68
2426,accelerator,1.67
2427,mersana,1.6666666666666667
2428,identical,1.6666666666666667
2429,estimates,1.6666666666666667
2430,material,1.6666666666666667
2431,derivatives,1.6666666666666667
2432,due,1.6666666666666667
2433,accrue,1.6666666666666667
2434,expects,1.6666666666666667
2435,believes,1.6666666666666667
2436,prospects,1.6666666666666667
2437,innovations,1.6666666666666667
2438,decides,1.6666666666666667
2439,firms,1.6666666666666667
2440,multiples,1.6666666666666667
2441,pension,1.6666666666666667
2442,termination,1.6666666666666667
2443,buyers,1.6666666666666667
2444,38 multiples,1.6666666666666667
2445,valuations,1.6639344262295082
2446,agreement,1.6615384615384616
2447,limited,1.65625
2448,conditions,1.6551724137931034
2449,investment,1.647887323943662
2450,000 investment,1.647887323943662
2451,012 investment,1.647887323943662
2452,round,1.646153846153846
2453,1 round,1.646153846153846
2454,discussed,1.6451612903225807
2455,payment,1.6434108527131783
2456,1 financing,1.6424581005586592
2457,financing,1.6424581005586592
2458,equal,1.6363636363636365
2459,equity,1.6317991631799162
2460,104 equity,1.6317991631799162
2461,20 equity,1.6317991631799162
2462,23 equity,1.6317991631799162
2463,higher,1.631578947368421
2464,proceeds,1.627906976744186
2465,made,1.6259541984732824
2466,present,1.625
2467,executed,1.625
2468,institutions,1.625
2469,entities,1.625
2470,definition,1.625
2471,partnership,1.625
2472,favorable,1.625
2473,deep,1.625
2474,asu,1.6222222222222222
2475,entered,1.619047619047619
2476,readily,1.6153846153846154
2477,ordinary,1.6153846153846154
2478,repurchased 298,1.6153846153846154
2479,repurchased 509,1.6153846153846154
2480,management,1.6126126126126126
2481,liability,1.6119402985074627
2482,factors,1.611764705882353
2483,certification,1.6111111111111112
2484,escrow,1.6083333333333334
2485,occur,1.606060606060606
2486,securities,1.6052287581699347
2487,investee,1.6
2488,techniques,1.6
2489,exit,1.6
2490,judgment,1.6
2491,accumulated,1.6
2492,execution,1.6
2493,repurchases,1.6
2494,ceased,1.6
2495,boy,1.6
2496,approximately 0,1.5909090909090908
2497,approximately 1,1.5909090909090908
2498,approximately 28,1.5909090909090908
2499,approximately $750,1.5909090909090908
2500,approximately $1,1.5909090909090908
2501,approximately,1.5909090909090908
2502,approximately 2,1.5909090909090908
2503,approximately $2,1.5909090909090908
2504,approximately 11,1.5909090909090908
2505,approximately 12,1.5909090909090908
2506,approximately 18,1.5909090909090908
2507,approximately 30,1.5909090909090908
2508,permitted,1.588235294117647
2509,money,1.588235294117647
2510,affect,1.5846153846153845
2511,nature,1.5833333333333333
2512,impact,1.5794392523364487
2513,carrying,1.5789473684210527
2514,consisting,1.5714285714285714
2515,inventions,1.5714285714285714
2516,goal,1.5714285714285714
2517,unrestricted,1.5714285714285714
2518,negotiated,1.5714285714285714
2519,calculate,1.5714285714285714
2520,transactions,1.5698924731182795
2521,values,1.5662650602409638
2522,provide,1.5631067961165048
2523,contingent,1.5625
2524,date,1.5620915032679739
2525,added,1.5555555555555556
2526,transferred,1.5555555555555556
2527,nanoscale,1.5555555555555556
2528,fourth,1.5555555555555556
2529,disease,1.5555555555555556
2530,success,1.5555555555555556
2531,consolidation,1.55
2532,acquiring,1.5454545454545454
2533,volume,1.5454545454545454
2534,selling,1.5454545454545454
2535,sources,1.5434782608695652
2536,formed,1.5384615384615385
2537,grant,1.5357142857142858
2538,milestones,1.5350877192982457
2539,government,1.5348837209302326
2540,maturities,1.5263157894736843
2541,full,1.5256410256410255
2542,12 full,1.5256410256410255
2543,investments,1.5233644859813085
2544,104 investments,1.5233644859813085
2545,75 investments,1.5233644859813085
2546,valued,1.5228426395939085
2547,amount,1.5220125786163523
2548,company,1.5199131064446054
2549,increases,1.5180722891566265
2550,commission,1.5172413793103448
2551,inputs,1.5142857142857142
2552,years,1.503875968992248
2553,10 years,1.503875968992248
2554,15 years,1.503875968992248
2555,27 years,1.503875968992248
2556,2 years,1.503875968992248
2557,13 years,1.503875968992248
2558,6 years,1.503875968992248
2559,5 years,1.503875968992248
2560,0 years,1.503875968992248
2561,responsible,1.5
2562,discounted,1.5
2563,closed,1.5
2564,parties,1.5
2565,methodologies,1.5
2566,preparation,1.5
2567,records,1.5
2568,vest,1.5
2569,landlord,1.5
2570,dollars,1.5
2571,currencies,1.5
2572,judgments,1.5
2573,presents,1.5
2574,circumstances,1.5
2575,registration,1.5
2576,profitability,1.5
2577,registered,1.5
2578,sections 55,1.5
2579,areas,1.5
2580,decade,1.5
2581,leveraging,1.5
2582,building,1.5
2583,realizing,1.5
2584,enum,1.5
2585,dollar,1.5
2586,stages,1.5
2587,backward,1.5
2588,nvca,1.5
2589,inherently,1.5
2590,recognize,1.5
2591,support,1.5
2592,complex,1.5
2593,signed,1.5
2594,targeting,1.5
2595,accomplishments,1.5
2596,longer,1.5
2597,rule 10,1.5
2598,rule,1.5
2599,length,1.5
2600,generally,1.4912280701754386
2601,reflect,1.4878048780487805
2602,property,1.4848484848484849
2603,federal,1.4814814814814814
2604,satisfy,1.48
2605,fund,1.48
2606,table,1.4791666666666667
2607,difficult,1.4782608695652173
2608,bdc,1.4782608695652173
2609,sales,1.476923076923077
2610,&quot,1.475037821482602
2611,investors,1.4743589743589745
2612,post,1.4736842105263157
2613,repurchase,1.4666666666666666
2614,owing,1.4663865546218486
2615,955 owing,1.4663865546218486
2616,338 owing,1.4663865546218486
2617,884 owing,1.4663865546218486
2618,567 owing,1.4663865546218486
2619,656 owing,1.4663865546218486
2620,2015 owing,1.4663865546218486
2621,564 owing,1.4663865546218486
2622,conversion,1.4615384615384615
2623,investing,1.4615384615384615
2624,raised,1.4615384615384615
2625,impactful,1.4615384615384615
2626,calculated,1.4594594594594594
2627,set,1.4583333333333333
2628,classes,1.4545454545454546
2629,amortization,1.4545454545454546
2630,plans,1.4545454545454546
2631,event,1.4545454545454546
2632,identify,1.4545454545454546
2633,point,1.4545454545454546
2634,dilution,1.4545454545454546
2635,premium,1.4444444444444444
2636,writes,1.4444444444444444
2637,withheld,1.4444444444444444
2638,gaap,1.4363636363636363
2639,observable,1.434782608695652
2640,exercised,1.434782608695652
2641,fair,1.4334038054968288
2642,recorded,1.4318181818181819
2643,risks,1.4285714285714286
2644,ric,1.4285714285714286
2645,successful,1.4166666666666667
2646,effect,1.4166666666666667
2647,lead,1.4137931034482758
2648,maturity,1.4090909090909092
2649,focus,1.4090909090909092
2650,73 maturity,1.4090909090909092
2651,series,1.4081632653061225
2652,terms,1.403225806451613
2653,healthcare,1.4
2654,measure,1.4
2655,materially,1.4
2656,standard,1.4
2657,monetize,1.4
2658,level,1.3978494623655915
2659,level,1.3978494623655915
2660,level,1.3978494623655915
2661,level,1.3978494623655915
2662,75 level,1.3978494623655915
2663,stated,1.375
2664,lesser,1.375
2665,history,1.375
2666,access,1.375
2667,representation,1.375
2668,range,1.375
2669,% range,1.375
2670,adjustments,1.3703703703703705
2671,warrant,1.3703703703703705
2672,ownership,1.3692307692307693
2673,time,1.3585657370517927
2674,pursuant,1.3571428571428572
2675,sets,1.3571428571428572
2676,abatements,1.3571428571428572
2677,disclosures,1.3548387096774193
2678,liabilities,1.353448275862069
2679,consideration,1.35
2680,resulted,1.35
2681,estimate,1.3488372093023255
2682,shares,1.3471264367816091
2683,394 shares,1.3471264367816091
2684,291 shares,1.3471264367816091
2685,368 shares,1.3471264367816091
2686,760 shares,1.3471264367816091
2687,325 shares,1.3471264367816091
2688,658 shares,1.3471264367816091
2689,897 shares,1.3471264367816091
2690,000 shares,1.3471264367816091
2691,295 shares,1.3471264367816091
2692,120 shares,1.3471264367816091
2693,796 shares,1.3471264367816091
2694,039 shares,1.3471264367816091
2695,756 shares,1.3471264367816091
2696,834 shares,1.3471264367816091
2697,833 shares,1.3471264367816091
2698,819 shares,1.3471264367816091
2699,365 shares,1.3471264367816091
2700,082 shares,1.3471264367816091
2701,868 shares,1.3471264367816091
2702,860 shares,1.3471264367816091
2703,761 shares,1.3471264367816091
2704,530 shares,1.3471264367816091
2705,938 shares,1.3471264367816091
2706,335 shares,1.3471264367816091
2707,618 shares,1.3471264367816091
2708,461 shares,1.3471264367816091
2709,465 shares,1.3471264367816091
2710,located,1.3333333333333333
2711,iii,1.3333333333333333
2712,record,1.3333333333333333
2713,largest,1.3333333333333333
2714,yields,1.3333333333333333
2715,targets,1.3333333333333333
2716,application,1.3333333333333333
2717,otisville,1.3333333333333333
2718,trends,1.3333333333333333
2719,agreed,1.3333333333333333
2720,administration,1.3333333333333333
2721,member,1.3333333333333333
2722,applied,1.3333333333333333
2723,amends,1.3333333333333333
2724,leases,1.3333333333333333
2725,occurred,1.3333333333333333
2726,iasb,1.3333333333333333
2727,collaboration,1.3333333333333333
2728,alzheimer,1.3333333333333333
2729,transfers,1.3278688524590163
2730,1 transfers,1.3278688524590163
2731,3 transfers,1.3278688524590163
2732,entity,1.3265306122448979
2733,december31,1.3255813953488371
2734,code,1.325
2735,short,1.3225806451612903
2736,approval,1.3225806451612903
2737,results,1.3203125
2738,trade,1.3181818181818181
2739,ventures,1.3166666666666667
2740,decreases,1.3157894736842106
2741,employees,1.3150684931506849
2742,rights,1.313953488372093
2743,amended,1.3125
2744,share,1.3082437275985663
2745,return,1.3076923076923077
2746,limit,1.3
2747,assignment,1.3
2748,advantage,1.3
2749,shareholders,1.3
2750,past,1.3
2751,measured,1.2941176470588236
2752,methods,1.2857142857142858
2753,prospectively,1.2857142857142858
2754,exercisable,1.2857142857142858
2755,completed,1.2857142857142858
2756,pipeline,1.2857142857142858
2757,maturing,1.2857142857142858
2758,excluding,1.2857142857142858
2759,leading,1.2857142857142858
2760,ipo,1.2765957446808511
2761,sold,1.2765957446808511
2762,sold 25,1.2765957446808511
2763,sold 769,1.2765957446808511
2764,sold 50,1.2765957446808511
2765,sold 1,1.2765957446808511
2766,sold 98,1.2765957446808511
2767,guidance,1.2758620689655173
2768,write,1.2735849056603774
2769,considered,1.2727272727272727
2770,defined,1.2692307692307692
2771,announced,1.2666666666666666
2772,beginning,1.2641509433962264
2773,synglyco,1.263157894736842
2774,review,1.263157894736842
2775,change,1.2586206896551724
2776,operations,1.2583732057416268
2777,historically,1.2564102564102564
2778,transaction,1.25
2779,progress,1.25
2780,disposition,1.25
2781,volatilities,1.25
2782,enterprise,1.25
2783,phylagen,1.25
2784,receivable,1.25
2785,driven,1.25
2786,situation,1.25
2787,restrictions,1.2439024390243902
2788,recognized,1.24
2789,achieved,1.2380952380952381
2790,meet,1.2380952380952381
2791,drawdown,1.2380952380952381
2792,section,1.2363636363636363
2793,section,1.2363636363636363
2794,section,1.2363636363636363
2795,section,1.2363636363636363
2796,note 3,1.2320441988950277
2797,note 11,1.2320441988950277
2798,note,1.2320441988950277
2799,note 1,1.2320441988950277
2800,note 5,1.2320441988950277
2801,note 9,1.2320441988950277
2802,note 10,1.2320441988950277
2803,note 4,1.2320441988950277
2804,note,1.2320441988950277
2805,note 8,1.2320441988950277
2806,note 13,1.2320441988950277
2807,note 6,1.2320441988950277
2808,note 12,1.2320441988950277
2809,note 14,1.2320441988950277
2810,note 7,1.2320441988950277
2811,note 15,1.2320441988950277
2812,maintain,1.2307692307692308
2813,adjustment,1.2307692307692308
2814,issue,1.2222222222222223
2815,measurements,1.2173913043478262
2816,board,1.2160493827160495
2817,seats,1.2142857142857142
2818,times,1.2142857142857142
2819,bridgelux,1.2142857142857142
2820,pre,1.2121212121212122
2821,structured,1.2105263157894737
2822,timing,1.205128205128205
2823,calculation,1.2
2824,distribute,1.2
2825,discounts,1.2
2826,variations,1.2
2827,orig3n,1.2
2828,asc 820,1.2
2829,xenio,1.2
2830,increase,1.1959183673469387
2831,quarter,1.1954887218045114
2832,quarter,1.1954887218045114
2833,uncertainties,1.1951219512195121
2834,interome,1.1935483870967742
2835,directors,1.190217391304348
2836,technology,1.1891891891891893
2837,percent,1.188095238095238
2838,25 percent,1.188095238095238
2839,70 percent,1.188095238095238
2840,200 percent,1.188095238095238
2841,82 percent,1.188095238095238
2842,9 percent,1.188095238095238
2843,12 percent,1.188095238095238
2844,10 percent,1.188095238095238
2845,3 percent,1.188095238095238
2846,5 percent,1.188095238095238
2847,0 percent,1.188095238095238
2848,90 percent,1.188095238095238
2849,98 percent,1.188095238095238
2850,2 percent,1.188095238095238
2851,100 percent,1.188095238095238
2852,85 percent,1.188095238095238
2853,79 percent,1.188095238095238
2854,6 percent,1.188095238095238
2855,8 percent,1.188095238095238
2856,4 percent,1.188095238095238
2857,7 percent,1.188095238095238
2858,1 percent,1.188095238095238
2859,83 percent,1.188095238095238
2860,95 percent,1.188095238095238
2861,11 percent,1.188095238095238
2862,16 percent,1.188095238095238
2863,18 percent,1.188095238095238
2864,50 percent,1.188095238095238
2865,15 percent,1.188095238095238
2866,08 percent,1.188095238095238
2867,025 percent,1.188095238095238
2868,sionyx,1.1875
2869,indirectly,1.1875
2870,concern,1.1666666666666667
2871,reports,1.1666666666666667
2872,equipment,1.1666666666666667
2873,interests,1.1666666666666667
2874,matures,1.1666666666666667
2875,borrowings,1.1666666666666667
2876,reflected,1.1666666666666667
2877,commercialization,1.1666666666666667
2878,shift,1.1666666666666667
2879,manage,1.1666666666666667
2880,invest,1.1559633027522935
2881,included,1.1546391752577319
2882,hierarchy,1.1515151515151516
2883,make,1.1515151515151516
2884,sale,1.1486880466472302
2885,measurement,1.1470588235294117
2886,expect,1.1470588235294117
2887,represents,1.1428571428571428
2888,amortized,1.1428571428571428
2889,decline,1.1428571428571428
2890,ups,1.1428571428571428
2891,2 represents,1.1428571428571428
2892,3 represents,1.1428571428571428
2893,4 represents,1.1428571428571428
2894,1 represents,1.1428571428571428
2895,require,1.135135135135135
2896,manner,1.125
2897,5 million,1.125
2898,4 million,1.125
2899,efforts,1.125
2900,$30 million,1.125
2901,7 million,1.125
2902,8 million,1.125
2903,late,1.125
2904,facilitate,1.125
2905,3 million,1.125
2906,$20 million,1.125
2907,2 million,1.125
2908,comprised,1.119047619047619
2909,sell,1.119047619047619
2910,met,1.1176470588235294
2911,number,1.1176470588235294
2912,offset,1.1166666666666667
2913,volatile,1.1153846153846154
2914,decrease,1.104089219330855
2915,338 decrease,1.104089219330855
2916,llc,1.103448275862069
2917,hold,1.0980392156862746
2918,control,1.0972222222222223
2919,positions,1.096774193548387
2920,result,1.0925925925925926
2921,revenues,1.0909090909090908
2922,forward,1.0909090909090908
2923,subject,1.088235294117647
2924,determined,1.0851063829787233
2925,continue,1.0843373493975903
2926,regulation,1.0833333333333333
2927,called,1.0833333333333333
2928,form 10,1.0819672131147542
2929,form,1.0819672131147542
2930,608 follow,1.0746268656716418
2931,000 follow,1.0746268656716418
2932,003 follow,1.0746268656716418
2933,006 follow,1.0746268656716418
2934,follow,1.0746268656716418
2935,290 follow,1.0746268656716418
2936,272 follow,1.0746268656716418
2937,portion,1.0704225352112675
2938,extent,1.069767441860465
2939,purchase 277,1.0666666666666667
2940,distributed,1.0666666666666667
2941,purchase,1.0666666666666667
2942,purchase 0,1.0666666666666667
2943,hzo,1.064516129032258
2944,summary,1.0638297872340425
2945,downs,1.0638297872340425
2946,acquisition,1.0617283950617284
2947,acquire,1.0571428571428572
2948,warrants,1.0518518518518518
2949,833 warrants,1.0518518518518518
2950,accounted,1.0517241379310345
2951,opgen,1.0512820512820513
2952,ability,1.0490196078431373
2953,repayment,1.0476190476190477
2954,carried,1.0454545454545454
2955,apply,1.0434782608695652
2956,january 31,1.0416666666666667
2957,january 2015,1.0416666666666667
2958,january 21,1.0416666666666667
2959,january 1,1.0416666666666667
2960,january 5,1.0416666666666667
2961,november 17,1.03125
2962,november,1.03125
2963,november,1.03125
2964,november,1.03125
2965,november,1.03125
2966,november,1.03125
2967,november,1.03125
2968,november,1.03125
2969,types,1.0303030303030303
2970,compared,1.0188679245283019
2971,march,1.0100502512562815
2972,march,1.0100502512562815
2973,march 7,1.0100502512562815
2974,march 31,1.0100502512562815
2975,march 18,1.0100502512562815
2976,march,1.0100502512562815
2977,march 30,1.0100502512562815
2978,march 15,1.0100502512562815
2979,september 30,1.0046948356807512
2980,september,1.0046948356807512
2981,june,1.0045871559633028
2982,june,1.0045871559633028
2983,june,1.0045871559633028
2984,june,1.0045871559633028
2985,june,1.0045871559633028
2986,june,1.0045871559633028
2987,item,1.0
2988,opinion,1.0
2989,elected,1.0
2990,operate,1.0
2991,accordance,1.0
2992,america,1.0
2993,condensed,1.0
2994,omitted,1.0
2995,conformity,1.0
2996,read,1.0
2997,conjunction,1.0
2998,footnote,1.0
2999,page,1.0
3000,description,1.0
3001,seek,1.0
3002,productivity,1.0
3003,efficiency,1.0
3004,waste,1.0
3005,computing,1.0
3006,agriculture,1.0
3007,chemicals,1.0
3008,bioprocessing,1.0
3009,food,1.0
3010,nutrition,1.0
3011,pledged,1.0
3012,collateral,1.0
3013,july,1.0
3014,acquired,1.0
3015,close,1.0
3016,ascribed,1.0
3017,canada,1.0
3018,prosep,1.0
3019,august,1.0
3020,reorganized,1.0
3021,uberseq,1.0
3022,transfer,1.0
3023,lock,1.0
3024,restricts,1.0
3025,exclusive,1.0
3026,july,1.0
3027,repaid $567,1.0
3028,minus,1.0
3029,contingencies,1.0
3030,december,1.0
3031,achievement,1.0
3032,cancel,1.0
3033,impossible,1.0
3034,achieve,1.0
3035,canon,1.0
3036,spin,1.0
3037,retained,1.0
3038,filed,1.0
3039,assurances,1.0
3040,determination,1.0
3041,determine,1.0
3042,direction,1.0
3043,ensuring,1.0
3044,recommendations,1.0
3045,liquidated,1.0
3046,end,1.0
3047,prepared,1.0
3048,practicable,1.0
3049,communicated,1.0
3050,terminology,1.0
3051,utilized,1.0
3052,long,1.0
3053,selection,1.0
3054,derive,1.0
3055,significance,1.0
3056,relevance,1.0
3057,deriving,1.0
3058,earnings,1.0
3059,scholes,1.0
3060,multi,1.0
3061,elements,1.0
3062,individually,1.0
3063,probability,1.0
3064,directly,1.0
3065,instances,1.0
3066,classified,1.0
3067,indication,1.0
3068,patents,1.0
3069,research,1.0
3070,ebitda,1.0
3071,proportion,1.0
3072,class,1.0
3073,valuing,1.0
3074,broker,1.0
3075,dealers,1.0
3076,60 days,1.0
3077,patent,1.0
3078,dispositions,1.0
3079,frequency,1.0
3080,advance,1.0
3081,filing,1.0
3082,48 hours,1.0
3083,sundays,1.0
3084,holidays,1.0
3085,accuracy,1.0
3086,preparing,1.0
3087,highlight,1.0
3088,fixtures,1.0
3089,reviewed,1.0
3090,responsibility,1.0
3091,specializes,1.0
3092,officers,1.0
3093,conduct,1.0
3094,taxed,1.0
3095,subchapter,1.0
3096,instructions,1.0
3097,article,1.0
3098,principles,1.0
3099,consolidate,1.0
3100,eliminated,1.0
3101,reclassified,1.0
3102,conform,1.0
3103,earnings/,1.0
3104,difference,1.0
3105,amgen,1.0
3106,assurance,1.0
3107,released,1.0
3108,april,1.0
3109,connection,1.0
3110,capitalized,1.0
3111,straight,1.0
3112,lives,1.0
3113,furniture,1.0
3114,000 multi,1.0
3115,borrower,1.0
3116,lender,1.0
3117,terminated,1.0
3118,reduction,1.0
3119,accretion,1.0
3120,recoverable,1.0
3121,offs,1.0
3122,reversed,1.0
3123,intention,1.0
3124,sells,1.0
3125,grants,1.0
3126,additionally,1.0
3127,expensing,1.0
3128,intends,1.0
3129,qualify,1.0
3130,revised,1.0
3131,discussion,1.0
3132,1450 broadway,1.0
3133,commenced,1.0
3134,credits,1.0
3135,escalations,1.0
3136,behalf,1.0
3137,depreciated,1.0
3138,california,1.0
3139,disposed,1.0
3140,computed,1.0
3141,intend,1.0
3142,penalties,1.0
3143,state,1.0
3144,maintained,1.0
3145,translated,1.0
3146,isolate,1.0
3147,arises,1.0
3148,exceed,1.0
3149,april,1.0
3150,simplifying,1.0
3151,december,1.0
3152,anticipated,1.0
3153,restrict,1.0
3154,provisions,1.0
3155,rebalance,1.0
3156,rest,1.0
3157,vulnerable,1.0
3158,unrelated,1.0
3159,metabolon,1.0
3160,typically,1.0
3161,things,1.0
3162,annum,1.0
3163,arrears,1.0
3164,prepay,1.0
3165,loans,1.0
3166,affirmative,1.0
3167,limitation,1.0
3168,maintenance,1.0
3169,limitations,1.0
3170,liens,1.0
3171,incurrence,1.0
3172,structural,1.0
3173,mergers,1.0
3174,establishing,1.0
3175,compliance,1.0
3176,develop,1.0
3177,merger,1.0
3178,marketability,1.0
3179,unable,1.0
3180,shut,1.0
3181,assess,1.0
3182,assessment,1.0
3183,evaluation,1.0
3184,outcome,1.0
3185,type,1.0
3186,entitled,1.0
3187,achievements,1.0
3188,case,1.0
3189,failing,1.0
3190,components,1.0
3191,972 transfer,1.0
3192,qualification,1.0
3193,conversions,1.0
3194,000 transfer,1.0
3195,administer,1.0
3196,retirees,1.0
3197,spouses,1.0
3198,age,1.0
3199,grandfathered,1.0
3200,salaries,1.0
3201,april,1.0
3202,respect,1.0
3203,multiplied,1.0
3204,cover,1.0
3205,delivered,1.0
3206,recipient,1.0
3207,represented,1.0
3208,reducing,1.0
3209,treated,1.0
3210,rics,1.0
3211,annually,1.0
3212,retain,1.0
3213,fail,1.0
3214,furnishing,1.0
3215,corporations,1.0
3216,exploitation,1.0
3217,processes,1.0
3218,addition,1.0
3219,qualified,1.0
3220,action,1.0
3221,ensure,1.0
3222,computation,1.0
3223,anti,1.0
3224,dilutive,1.0
3225,default,1.0
3226,contribute,1.0
3227,withdrawal,1.0
3228,july,1.0
3229,july,1.0
3230,july,1.0
3231,august,1.0
3232,promuc,1.0
3233,august,1.0
3234,august 7,1.0
3235,agbiome,1.0
3236,item,1.0
3237,annualized,1.0
3238,65 item,1.0
3239,projections,1.0
3240,beliefs,1.0
3241,words,1.0
3242,anticipates,1.0
3243,seeks,1.0
3244,projects,1.0
3245,intended,1.0
3246,relationships,1.0
3247,dependence,1.0
3248,objectives,1.0
3249,adequacy,1.0
3250,monetization,1.0
3251,guarantees,1.0
3252,predict,1.0
3253,expressed,1.0
3254,forecasted,1.0
3255,impair,1.0
3256,contraction,1.0
3257,inability,1.0
3258,elect,1.0
3259,leverage,1.0
3260,filings,1.0
3261,prove,1.0
3262,inaccurate,1.0
3263,originate,1.0
3264,margins,1.0
3265,availability,1.0
3266,inclusion,1.0
3267,projection,1.0
3268,regarded,1.0
3269,background,1.0
3270,incorporated,1.0
3271,august 1981,1.0
3272,divested,1.0
3273,overview,1.0
3274,multidisciplinary,1.0
3275,microscale,1.0
3276,overlap,1.0
3277,biology,1.0
3278,intersecting,1.0
3279,physics,1.0
3280,chemistry,1.0
3281,engineering,1.0
3282,mathematics,1.0
3283,nanotechnology,1.0
3284,microtechnology,1.0
3285,observed,1.0
3286,execute,1.0
3287,participate,1.0
3288,echopixel,1.0
3289,letters,1.0
3290,recently,1.0
3291,home,1.0
3292,run,1.0
3293,excess,1.0
3294,opportunity,1.0
3295,built,1.0
3296,leaders,1.0
3297,internet,1.0
3298,iot,1.0
3299,microbiome,1.0
3300,positioned,1.0
3301,size,1.0
3302,disconnect,1.0
3303,utilizing,1.0
3304,initiated,1.0
3305,implemented,1.0
3306,extended,1.0
3307,discontinued,1.0
3308,inaccessible,1.0
3309,organize,1.0
3310,finally,1.0
3311,refers,1.0
3312,nantero,1.0
3313,solazyme,1.0
3314,kovio,1.0
3315,february 19,1.0
3316,august 15,1.0
3317,stockholders,1.0
3318,dissolution,1.0
3319,approved,1.0
3320,majority,1.0
3321,acquisitions,1.0
3322,points,1.0
3323,april,1.0
3324,consumer,1.0
3325,opgnw,1.0
3326,inclusive,1.0
3327,july,1.0
3328,acceleration,1.0
3329,bring,1.0
3330,august 2015,1.0
3331,begin,1.0
3332,process,1.0
3333,ipos,1.0
3334,advisors,1.0
3335,attempt,1.0
3336,pursue,1.0
3337,tangible,1.0
3338,acceptance,1.0
3339,intent,1.0
3340,stronger,1.0
3341,liquidating,1.0
3342,nanoterra,1.0
3343,ultora,1.0
3344,july,1.0
3345,august,1.0
3346,mid,1.0
3347,shown,1.0
3348,figure,1.0
3349,transition,1.0
3350,accompanied,1.0
3351,implications,1.0
3352,studying,1.0
3353,evident,1.0
3354,steps,1.0
3355,involvement,1.0
3356,membership,1.0
3357,boards,1.0
3358,observers,1.0
3359,uplisting,1.0
3360,formation,1.0
3361,banking,1.0
3362,knowledge,1.0
3363,running,1.0
3364,micro,1.0
3365,depicts,1.0
3366,noted,1.0
3367,realization,1.0
3368,leader,1.0
3369,confined,1.0
3370,addressing,1.0
3371,adjust,1.0
3372,magnitude,1.0
3373,diagnostics,1.0
3374,grow,1.0
3375,telecommunications,1.0
3376,metrology,1.0
3377,test,1.0
3378,undrawn,1.0
3379,examine,1.0
3380,assessing,1.0
3381,strength,1.0
3382,receivables,1.0
3383,add,1.0
3384,twenty,1.0
3385,4 billion,1.0
3386,compounded,1.0
3387,fact,1.0
3388,acute,1.0
3389,favor,1.0
3390,difficulties,1.0
3391,forced,1.0
3392,reaching,1.0
3393,translate,1.0
3394,finance,1.0
3395,illiquidity,1.0
3396,perception,1.0
3397,cases,1.0
3398,calculates,1.0
3399,sum,1.0
3400,derivation,1.0
3401,referred,1.0
3402,backsolve,1.0
3403,calculations,1.0
3404,redemptions,1.0
3405,honored,1.0
3406,scenario,1.0
3407,parity,1.0
3408,percentage,1.0
3409,trades,1.0
3410,nanosys,1.0
3411,relied,1.0
3412,rely,1.0
3413,defray,1.0
3414,unpredictable,1.0
3415,occurrence,1.0
3416,inflation,1.0
3417,quantity,1.0
3418,duration,1.0
3419,variation,1.0
3420,durations,1.0
3421,resignation,1.0
3422,expiration,1.0
3423,xradia,1.0
3424,exploration,1.0
3425,additions,1.0
3426,reinvestment,1.0
3427,establishes,1.0
3428,framework,1.0
3429,focuses,1.0
3430,advantageous,1.0
3431,prioritizes,1.0
3432,transparency,1.0
3433,creditworthiness,1.0
3434,quantified,1.0
3435,subjectivity,1.0
3436,indicating,1.0
3437,calculating,1.0
3438,assumes,1.0
3439,assumed,1.0
3440,adjusting,1.0
3441,changed,1.0
3442,statistical,1.0
3443,mortality,1.0
3444,estimating,1.0
3445,page,1.0
3446,creditors,1.0
3447,october,1.0
3448,october,1.0
3449,october,1.0
3450,august 19,1.0
3451,concentration,1.0
3452,disposal,1.0
3453,obligated,1.0
3454,comply,1.0
3455,prohibitions,1.0
3456,conducted,1.0
3457,commissions,1.0
3458,leaving,1.0
3459,maximum,1.0
3460,iots,1.0
3461,october,1.0
3462,20 inclusive,1.0
3463,december,1.0
3464,wellbeing,1.0
3465,ahead,1.0
3466,prevalent,1.0
3467,phenotypic,1.0
3468,shifted,1.0
3469,reorganization,1.0
3470,exist,1.0
3471,august 12,1.0
3472,travel,1.0
3473,cancellation,1.0
3474,page,1.0
3475,person,1.0
3476,april 25,1.0
3477,august,1.0
3478,february,1.0
3479,april,1.0
3480,release,1.0
3481,incurs,1.0
3482,deliver,1.0
3483,exceeds,1.0
3484,april,1.0
3485,august 18,1.0
3486,arrangement,1.0
3487,adopted,1.0
3488,february 18,1.0
3489,topic,1.0
3490,customers,1.0
3491,depict,1.0
3492,goods,1.0
3493,july,1.0
3494,approve,1.0
3495,meaning,1.0
3496,evaluated,1.0
3497,topic,1.0
3498,august 27,1.0
3499,disclosure,1.0
3500,disclose,1.0
3501,february 25,1.0
3502,topic,1.0
3503,lessees,1.0
3504,pattern,1.0
3505,lessor,1.0
3506,simplify,1.0
3507,aspects,1.0
3508,conversely,1.0
3509,958 transfer,1.0
3510,reversal,1.0
3511,obtain,1.0
3512,grown,1.0
3513,pass,1.0
3514,performing,1.0
3515,opt,1.0
3516,february 6,1.0
3517,april,1.0
3518,april,1.0
3519,66 item,1.0
3520,identifying,1.0
3521,operational,1.0
3522,genetic,1.0
3523,influence,1.0
3524,exert,1.0
3525,flexibility,1.0
3526,founded,1.0
3527,launched,1.0
3528,clearance,1.0
3529,xmt,1.0
3530,fda,1.0
3531,antibody,1.0
3532,takeda,1.0
3533,faced,1.0
3534,challenges,1.0
3535,headwinds,1.0
3536,challenge,1.0
3537,seeking,1.0
3538,categorize,1.0
3539,predicated,1.0
3540,affected,1.0
3541,linked,1.0
3542,negotiations,1.0
3543,supportive,1.0
3544,situations,1.0
3545,occurring,1.0
3546,frequently,1.0
3547,dominated,1.0
3548,reason,1.0
3549,impacted,1.0
3550,oil,1.0
3551,exposure,1.0
3552,adverse,1.0
3553,leads,1.0
3554,uncertainty,1.0
3555,engagements,1.0
3556,split,1.0
3557,expiring,1.0
3558,page,1.0
3559,august,1.0
3560,licenses,1.0
3561,july,1.0
3562,431 transfer,1.0
3563,master,1.0
3564,april,1.0
3565,summarized,1.0
3566,july,1.0
3567,july,1.0
3568,july,1.0
3569,satisfied,1.0
3570,organizer,1.0
3571,august,1.0
3572,deviate,1.0
3573,decide,1.0
3574,occurs,1.0
3575,recapitalization,1.0
3576,counter,1.0
3577,october,1.0
3578,october,1.0
3579,modify,1.0
3580,finalize,1.0
3581,allocations,1.0
3582,october,1.0
3583,october,1.0
3584,recover,1.0
3585,department,1.0
